|
Life Science Instruments
Company Announcements
Standard BioTools’ fourth quarter 2023 sales grew 4.3% to $28.2 million. Non-GAAP adjusted EBITDA was a $7.5 million loss compared to a $11.1 million loss a year ago. Proteomics sales gained 21% to $16 million, while Genomics sales declined 13% to $12 million. Instrument sales rose 44% to $11 million and Service & Other sales increased 12% to $7 million, but Consumables sales were down 22% to $10 million.
Full-year 2023 sales for Standard BioTools rose 8.6% to $106.3 million. Non-GAAP adjusted EBITDA loss totaled $34.7 million compared to a loss of $68.9 million for 2022. Proteomics sales rose 21.7% to make up 60% of revenues. Genomics revenue declined 6.6% to account for the remainder and was down 4% excluding discontinued products. One customer accounted for 10% of Genomics revenue. Instrument sales led placements of the Hyperion XTi imaging system, and Service & Other sales rose 46% and 6% to make up 36% and 25% of revenues, respectively. Consumables revenue fell 11% to represent 39%. Sales in the Americas, EMEA and Asia-Pacific rose 5.0%, 9.2% and 14.9% to account for 43%, 34% and 23% of revenues, respectively. Proforma combined revenues for Standard BioTools and SomaLogic, whose acquisition was completed in January, were $192 million, with SomaLogic contributing $86.1 million. SomaLogic core sales (excluding nonrecurring royalty revenue) grew 21%. During the year, the company increased the number of Certified Sites from eight to 17. Standard BioTools forecasts 2024 revenues of $200–$205 million for 4%–7% revenue growth.
Product Introductions
INTEGRA Biosciences announced in February the introduction of its MAG and HEATMAG modules for automated magnetic bead purification, which are designed to streamline several processing steps in molecular biology and proteomics workflows. They feature magnets that automatically move up and down for magnetic bead collection, removing the need to manually move plates and tubes to and from the magnet. These are complemented by the COLDPLATE and BIOSHAKE for temperature control and orbital shaking of magnetic beads, respectively.In March, NanoMosaic, a multiplex and multi-omic quantification company, announced expanded capabilities and availability of assays optimized on its Tessie system for use in gene therapy applications. The platform combines the ability to quantify proteins and nucleic acids in a single run, enabling the simultaneous detection and characterization of AAV capsids and of therapeutic transgenes. The assays are deployable across upstream and downstream stages of the gene therapy workflow, while harmonizing the data from bioprocessing to batch release QC.
Gene-Based Analysis
Company Announcements
In February, Hitachi High-Tech America (HTA), in conjunction with Nabsys, a genomic analysis solutions firm, announced HTA's planned acquisition of 50 of Nabsys’ OhmX instruments to support the joint RAMP UP (rapid application to market penetration user partnerships). The OhmX platform, which has been made available to select customers in early access, was released commercially in October 2023. The platform leverages electronic nanochannel detectors to scan labeled high molecular weight DNA and perform de novo genome assembly for structural variant analysis.In March, Nabsys announced a distribution agreement with Canadian distributor DMark Biosciences for the OhmX platform.
In February, Telesis Bio, a synthetic biology tools firm, announced preliminary financial results. Fourth quarter 2023 sales fell 26.3% to $7.0 million but included a 25.9% increase in BioXP kit revenue to more than $1.0 million. Collaboration revenue rose 30.7% to $8.7 million. Telesis Bio’s 2023 revenues were flat at $27.5 million as BioXp kit sales rose 10%. Excluding BioXp instrument sales and the discontinued BioFoundry Services operations, annual sales increased 12.4% to $20.9 million.
In February, Bionano Genomics, a provider of optical genome mapping technology (OGM), announced that it amended the convertible debt financing the company entered in October 2023, which had raised $80 million financing in convertible notes and warrants. The amendment resulted in $24.3 million in aggregate principal amount of the initial registered note outstanding. The new arrangement provides immediate access to $30.0 million of near-term liquidity. The company will also have access to up to an additional $25.0 million of liquidity from the restricted cash account that will now be available as the principal on the notes is retired instead of upon meeting certain funding conditions.
Bionano Genomics’ fourth quarter 2023 results grew 30.5% to $10.7 million (see Bottom Line). The number of nanochannel array flowcells sold increased 67.0% to 7,980. That company announced that 70% of orders related to its Stratys early access program were from new customers.
Full-year 2023 revenues for Bionano Genomics rose 29.9% to $36.1 million. The installed base grew 36% to 326 OGM systems. The company sold 26,444 flowcells for a 72% increase. Sales in the Americas, EMEA and Asia Pacific increased 30.0%, 44.7% and 3.1% to represent 50%, 36% and 14% of revenues, respectively. The company announced that to streamline its operating structure (see Executive Briefing) and focus on core OGM products, it is phasing out its First Step and Next Step Dx clinical services products and Fragile X test, which are legacy, non-OGM tests. In 2023, these products generated around $7.0 million in revenue. The company had cash, cash equivalents and available-for-sale securities of $102.3 million as of year-end.
Full-year 2024 Bionano Genomics revenues are expected to be $37.0–$41.0 million, with installation of 80–100 systems anticipated during the year, including some conversions from Saphyr to Stratys systems. First quarter revenues are expected to be $8.25–$8.75 million for growth of between 11% and 18%.
In March, Bio-Rad Laboratories announced that the AOAC approved its dd-Check STEC Solution for detecting and confirming virulence genes from Shiga toxin-producing Escherichia coli (STEC), in raw beef trim, fresh spinach and carcass sampling cloths. It is the first Droplet Digital PCR (ddPCR) method approved by AOAC. The approval of the method for confirmation signifies that the dd-Check STEC Solution is comparable to the standard reference method for confirmation of STEC.
Product Introductions
In December 2023, Omega Bio-tek, which offers nucleic acid purification systems and kits, introduced the MagBinder Fit for semi-automatic nucleic acid purification of high-quality DNA and RNA, stating it is the company’s first hardware for research labs isolating DNA samples for downstream analysis. The instrument, which the company calls affordable, utilizes coordinated magnetic rods to pick up, transfer and release magnetic particles within reagent cartridge wells. The MagBinder Fit24 works with both Omega Bio-tek Mag-Bind kits and specially designed MB Fit24 cartridges and comes with preloaded protocols. Prefilled kits available include MB Fit24 cfDNA Kit and MB Fit24 Blood & Tissue DNA Kit, with additional kits to be released in the future.
In February, Bio-Rad announced the launch of the Vericheck ddPCR Replication Competent Lentivirus Kit and the Vericheck ddPCR Replication Competent AAV Kit for the absolute quantification of replication competent lentivirus (RCL) and replication competent AAV (RCAAV) to support production of cell and gene therapies. The tests are designed for Bio-Rad's QX ddPCR platforms. Compared to traditional cell culture–based methods for RCV testing, the kits significantly reduce cost and turnaround time, achieving results in as little as eight hours, according to the company.
Cell-Based Analysis
Company Announcements
In January, Biocare Medical (Biocare), a provider of fully open automated instrumentation, announced a collaboration with Molecular Instruments (MI), a supplier of hybridization chain reaction (HCR) imaging technology. This partnership brings together Biocare Medical’s expertise in automated bioimaging systems with MI’s suite of HCR products for in situ automated ISH and IHC.In February, Singleron, which offers single-cell multi-omics solutions, announced the opening of its latest office and labs in Ann Arbor, Michigan. The office will feature a production and sales facility and provide a one-stop-shop single-cell analysis service, offering comprehensive solutions from tissue dissociation, single-cell multi-omic analysis, single-cell reagent kits, automation instruments and bioinformatics support. It complements the company’s existing New Haven, Connecticut, office. Founded in 2018, Singleron products are used in over 3,000 laboratories in hospitals, research institutes, and pharmaceutical companies in more than 20 countries.
Cell Microsystems, a provider of advanced tools for cell biology, announced in February a strategic partnership with OMNILife Science (OLS), a German cell biology company. This collaboration will introduce OLS’ CERO 3D cell culture incubator & bioreactor, CASY cell counter and analyzer, and TIGR tissue grinder & dissociator to the US and Canadian markets.
In February, Vizgen, a company providing solutions for visualizing single-cell spatial genomics information, announced a partnership with Scale Biosciences (ScaleBio) to combine their single-cell and spatial technologies for enhanced data analysis. As part of the strategic partnership, Vizgen and ScaleBio will generate high-resolution data from serial mouse brain tissue sections for single-cell RNA-seq, single-cell DNA methylation and targeted spatial gene expression. They will also be able to demonstrate the measurements from single cell RNA-seq, targeted spatial gene expression profiling and single nuclei DNA methylation to identify matching cell types, including all major cell types in the brain and subtypes of neurons. The matched datasets will also allow for integration of Vizgen’s targeted neuronal panel with spatial mapping and cell-typing with ScaleBio’s high-throughput single-cell RNA data which enables profiling of low-abundance cells and non-targeted gene expression to map to the spatial analysis.
Cytiva announced in February a collaboration with LevitasBio to deliver a single-cell workflow for genomics researchers in academia and industry that combines their respective VIA Extractor tissue disaggregator and LeviCell cell isolation and enrichment system. The collaboration is designed to improve how samples are prepared, enabling researchers to perform tasks more quickly like breaking down tissues and purifying individual cells suspensions for single-cell analysis and other downstream applications.
In February, Standard BioTools announced a collaboration agreement with Navignostics for development of clinical research applications and service offerings using the Standard BioTools’ Hyperion XTiImaging System for spatial single-cell proteomics. Founded in 2022, Navignostics goal is to identify the most effective treatment for each patient by using innovative tumor analysis methods. As part of the agreement, Standard BioTools will support the development of Navignostics assays by collaborating on various aspects of protocols and instrument and software features.
SAFIA Technologies (SAFIA) announced in February that it officially signed a distribution partnership with Sysmex Partec Flow Cytometry to address mycotoxins analysis in food & beverage and agriculture applications. SAFIA offers products based on its SAFIA (suspension array fluorescence immunoassay) technology utilizing a particle-based multiplex immunoassay.
In February, DNAnexus, the provider of the Precision Health Data Cloud, and spatial biology firm Curio Bioscience (Curio) announced a collaboration to streamline and simplify data analysis for high-resolution, whole transcriptome spatial mapping studies. As part of the agreement, Curio Seeker Spatial Mapping Kit customers will be able to use the DNAnexus Precision Health Data Cloud and its intuitive analysis environment to process the unbiased Curio Seeker data sets across different tissue types and species.
Acousort’s 2023 sales grew 11.5% to SEK 5.5 million ($0.5 million) (see Bottom Line). AcouSort’s acoustofluidics technology is designed to move cell types from one liquid to another, allowing fractionation of the different components in a blood sample, isolate extracellular vesicles, or wash cells to remove contaminants, without having any physical contact with the sample.
Braveheart Investments announced in March that because it was unable to secure an attractive decided it decided not to divest Paraytec. Paraytec offers the CX300 portable flow cytometer.
Akoya Biosciences’ fourth quarter 2023 sales grew 25.0% to $26.5 million (see Bottom Line). Reagent revenue gained 52% to $6.9 million. The company reported sales of 51 systems (15 PhenoCyclers, 36 PhenoImagers). Akoya Biosciences offers spatial biology solutions.
Full-year sales for Akoya Biosciences increased 29.0 % to $96.6 million. The installed base rose 26.7% to 1,183 (342 PhenoCyclers, 841 PhenoImagers) and included 205 PhenoCycler-Fusion systems. Instruments, Consumables, Standalone Software Products, and Service and Other sales grew 9.0%, 31.3%, 85.7% and 69.7% to account for 44%, 25%, 1% and 30% of revenues, respectively. Sales in North America, Europe and EMEA expanded 38.6%, 9.9% and 22.8% to represent 60%, 17% and 23% of revenues, respectively. 2024 revenues are expected to increase 18%–22% to $114–$118 million. The company ended the year with $83.1 million in cash and cash equivalents, and projects it will be operating cash flow breakeven by the end of 2024.
Flow cytometry firm Cytek Biosciences (Cytek) announced in March that it opened a new 50,000 ft2 (4,645 m2) facility in Wuxi, China. In addition to bolstering manufacturing capabilities, the facility also accommodates Cytek Wuxi operations, R&D, marketing, human resources, and sales teams.
Fourth quarter 2023 sales for Cytek Biosciences grew 21%, 14% in constant currency, to $58.6 million. Excluding revenue from the acquired Luminex product lines (see IBO 2/16/23), organic sales inched up 1% to $48.8 million. Adjusted EBITDA expanded 66.7% to $11.0 million. During the quarter, the company placed 152 instruments.
Cytek Biosiences’ 2023 sales increased 17.9%, up 13% in constant currency, to $193.4 million, but organic sales were flat. Luminex product line revenues totaled $28.7 million. The installed base was 2,148 instruments, increasing by 478 Cytek Bioscience placements and placement of 219 of Luminex’s Amnis and Guava systems. Adjusted EBITDA fell 35.4% to $13.7 million. US, EMEA, APAC and Other sales grew 7.9%, 21.0%, 40.3% and 107.7% to account for 53%, 28%, 16% and 3% of revenues, respectively. Academic and government made up 43% of customers and sales to them were up 11.4%, while pharma, biotech, distributor and CROs revenue made up 57% of sales with their sales up 22.7%. The company announced that its Cytek Cloud is utilized by more than 6,000 users. 2024 sales are forecast to increase 5%–10% to $203–$213 million, and the company anticipates positive net income in 2024.
Acousort’s 2023 sales grew 11.5% to SEK 5.5 million ($0.5 million) (see Bottom Line). AcouSort’s acoustofluidics technology is designed to move cell types from one liquid to another, allowing fractionation of the different components in a blood sample, isolate extracellular vesicles, or wash cells to remove contaminants, without having any physical contact with the sample.
Braveheart Investments announced in March that because it was unable to secure an attractive decided it decided not to divest Paraytec. Paraytec offers the CX300 portable flow cytometer.
Akoya Biosciences’ fourth quarter 2023 sales grew 25.0% to $26.5 million (see Bottom Line). Reagent revenue gained 52% to $6.9 million. The company reported sales of 51 systems (15 PhenoCyclers, 36 PhenoImagers). Akoya Biosciences offers spatial biology solutions.
Full-year sales for Akoya Biosciences increased 29.0 % to $96.6 million. The installed base rose 26.7% to 1,183 (342 PhenoCyclers, 841 PhenoImagers) and included 205 PhenoCycler-Fusion systems. Instruments, Consumables, Standalone Software Products, and Service and Other sales grew 9.0%, 31.3%, 85.7% and 69.7% to account for 44%, 25%, 1% and 30% of revenues, respectively. Sales in North America, Europe and EMEA expanded 38.6%, 9.9% and 22.8% to represent 60%, 17% and 23% of revenues, respectively. 2024 revenues are expected to increase 18%–22% to $114–$118 million. The company ended the year with $83.1 million in cash and cash equivalents, and projects it will be operating cash flow breakeven by the end of 2024.
Flow cytometry firm Cytek Biosciences (Cytek) announced in March that it opened a new 50,000 ft2 (4,645 m2) facility in Wuxi, China. In addition to bolstering manufacturing capabilities, the facility also accommodates Cytek Wuxi operations, R&D, marketing, human resources, and sales teams.
Fourth quarter 2023 sales for Cytek Biosciences grew 21%, 14% in constant currency, to $58.6 million. Excluding revenue from the acquired Luminex product lines (see IBO 2/16/23), organic sales inched up 1% to $48.8 million. Adjusted EBITDA expanded 66.7% to $11.0 million. During the quarter, the company placed 152 instruments.
Cytek Biosiences’ 2023 sales increased 17.9%, up 13% in constant currency, to $193.4 million, but organic sales were flat. Luminex product line revenues totaled $28.7 million. The installed base was 2,148 instruments, increasing by 478 Cytek Bioscience placements and placement of 219 of Luminex’s Amnis and Guava systems. Adjusted EBITDA fell 35.4% to $13.7 million. US, EMEA, APAC and Other sales grew 7.9%, 21.0%, 40.3% and 107.7% to account for 53%, 28%, 16% and 3% of revenues, respectively. Academic and government made up 43% of customers and sales to them were up 11.4%, while pharma, biotech, distributor and CROs revenue made up 57% of sales with their sales up 22.7%. The company announced that its Cytek Cloud is utilized by more than 6,000 users. 2024 sales are forecast to increase 5%–10% to $203–$213 million, and the company anticipates positive net income in 2024.
In February, DNAnexus, the provider of the Precision Health Data Cloud, and Curio announced a collaboration to streamline and simplify data analysis for high-resolution, whole transcriptome spatial mapping studies. As part of the agreement, Curio Seeker Spatial Mapping Kit customers will be able to use the DNAnexus Precision Health Data Cloud and its intuitive analysis environment to process the unbiased Curio Seeker data sets across different tissue types and species.
In February, CytoTronics, which develops semiconductor-based platforms for discovery in cell biology, announced its new Pixel. The system represents the company’s first commercial product based on its semiconductor-to-live-cell interface powered by microchips. Cells grow in culture media on top of a microarray containing over 100,000 nanoscale electrode-based sensors, allowing thousands of measurements to be taken per well, on any cell type or organoid system. The starting list price is under $30,000 for a Pixel Primo. Customers receive a Pixel Primo, a single plate reader that can be placed into any cell culture incubator, 96- well Pixel plates and Pixel Pro, a cloud-based control and interactive analysis software.
In February, Tecan announced its end-to-end cellomics workflow solutions, including cell seeding and culture with QC and monitoring, through drug dosing to live-cell imaging and analysis, to address challenges in 3D cell biology. The cellomics solutions include the recently launched Uno Single Cell Dispenser, the Fluent automated liquid handling workstation, the D300e Digital Dispenser, and the Spark Cyto. In an update scheduled for this year, the introduction of AI-based 3D analysis tools for Spark Cyto will further enhance capabilities.
Vizgen announced in February that its enhanced MERFISH chemistry, which extends sensitivity for degraded RNA samples, is scheduled to be available this summer. The company also announced that customers can now design custom panels capable of characterizing the expression of nearly 1,000 genes in the Vizgen Gene Panel Portal. Vizgen offers in situ single-cell spatial genomics technology.
In February, 10x Genomics, a single-cell and spatial biology company, debuted the GEM-X, the next generation of the company's single-cell technology and the first major overhaul to the Chromium architecture since the 2019 launch of Next GEM technology. GEM-X is built on a new and improved microfluidic chip design. Improvements include detection of up to two times more genes compared to on-market Chromium assays, a two-fold increase in cells captured per channel, a more than two-fold reduction in cost per cell and recovery of up to 80% of cells, according to 10x Genomics.
In March, 10x Genomics started shipping the first two products powered by the GEM-X technology architecture, Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3.
Curio announced in March the launch of an early access program for Curio Trekker, which the company calls the world’s first technology that spatially contextualizes single cell sequencing data. Using standard single-cell workflows, researchers will be able to use Curio Trekker to easily enhance single-cell and single-nuclei analyses with precise positional information at single-cell resolution, where this level of performance had previously been unavailable simultaneously, according to Curio. Curio signed a licensing agreement with the Broad Institute and is commercializing the technology. Curio is now taking pre-orders for the first commercial kits that are compatible with fresh frozen tissue sections. This technology will be easily applicable to a wide range of sample types, including FFPE, which Curio plans to launch in the second half of 2024.
Product Introductions
In February, ARRALYZE, the life science arm of LPKF Laser & Electronics, commercially released the CellShepherd cell screening system. The system features precise dispensing into nanoliter glass wells and supports (co)-culturing under climate-controlled, sterile conditions and is capable of real-time imaging through a brightfield microscope and three fluorescent channels.In February, CytoTronics, which develops semiconductor-based platforms for discovery in cell biology, announced its new Pixel. The system represents the company’s first commercial product based on its semiconductor-to-live-cell interface powered by microchips. Cells grow in culture media on top of a microarray containing over 100,000 nanoscale electrode-based sensors, allowing thousands of measurements to be taken per well, on any cell type or organoid system. The starting list price is under $30,000 for a Pixel Primo. Customers receive a Pixel Primo, a single plate reader that can be placed into any cell culture incubator, 96- well Pixel plates and Pixel Pro, a cloud-based control and interactive analysis software.
In February, Tecan announced its end-to-end cellomics workflow solutions, including cell seeding and culture with QC and monitoring, through drug dosing to live-cell imaging and analysis, to address challenges in 3D cell biology. The cellomics solutions include the recently launched Uno Single Cell Dispenser, the Fluent automated liquid handling workstation, the D300e Digital Dispenser, and the Spark Cyto. In an update scheduled for this year, the introduction of AI-based 3D analysis tools for Spark Cyto will further enhance capabilities.
Vizgen announced in February that its enhanced MERFISH chemistry, which extends sensitivity for degraded RNA samples, is scheduled to be available this summer. The company also announced that customers can now design custom panels capable of characterizing the expression of nearly 1,000 genes in the Vizgen Gene Panel Portal. Vizgen offers in situ single-cell spatial genomics technology.
In February, 10x Genomics, a single-cell and spatial biology company, debuted the GEM-X, the next generation of the company's single-cell technology and the first major overhaul to the Chromium architecture since the 2019 launch of Next GEM technology. GEM-X is built on a new and improved microfluidic chip design. Improvements include detection of up to two times more genes compared to on-market Chromium assays, a two-fold increase in cells captured per channel, a more than two-fold reduction in cost per cell and recovery of up to 80% of cells, according to 10x Genomics.
In March, 10x Genomics started shipping the first two products powered by the GEM-X technology architecture, Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3.
Curio announced in March the launch of an early access program for Curio Trekker, which the company calls the world’s first technology that spatially contextualizes single cell sequencing data. Using standard single-cell workflows, researchers will be able to use Curio Trekker to easily enhance single-cell and single-nuclei analyses with precise positional information at single-cell resolution, where this level of performance had previously been unavailable simultaneously, according to Curio. Curio signed a licensing agreement with the Broad Institute and is commercializing the technology. Curio is now taking pre-orders for the first commercial kits that are compatible with fresh frozen tissue sections. This technology will be easily applicable to a wide range of sample types, including FFPE, which Curio plans to launch in the second half of 2024.
Protein-Based Analysis
Company Announcements
Fiscal third quarter Biopharmaceutical Development sales for Mesa Laboratories declined 19.1% on an organic basis to $9.4 million (see Bottom Line), or 18% of total company sales. The division offers automated systems for protein analysis and peptide synthesis. Consumables and Services revenues grew 13.8% and 20.7% to make up 43% and 28% of Division revenue, while Hardware and Software revenue dropped 54.3% to account for 28%. The company ended the quarter with cash and cash equivalents of $28.2 million.In February, Nicoya, a life science instrument company specializing in biosensor technology, announced the appointment of Medispec as its exclusive distributor in India.
SkyWater Technology, a technology realization partner, announced in February it signed a production agreement with Nautilus Biotechnology (Nautilus) to supply silicon-based microfluidic biochips for Nautilus’ single-molecular proteome analysis platform.
Nautilus reported no revenues in 2023 (see Bottom Line). The firm expects to commercially launch its Nautilus instruments, consumables, and software in 2025. The first products were originally scheduled to be commercialized in 2024. Current research collaborations include with Genentech, Amgen, the University of Texas MD Anderson Cancer Center, and the City of Hope’s Translational Genomics Research Institute.
In February, Alamar Biosciences (Alamar), a company developing precision proteomics technology for disease detection, announced the first close of $100 million in Series C financing, with the second close of an additional $28 million expected to happen within the next 30 days. This new capital brings Alamar's total funding to date to nearly $250 million. The financing round was led by Sands Capital and included participation from new financial and strategic investors as well as existing major investors. Concurrent with the financing, Ian Ratcliffe, Executive Managing Partner of Sands Capital, joined the Board.
Quantum-Si’s 2023 sales were $1.1 million compared to no revenues in the prior year (see Bottom Line). Adjusted EBITDA was a loss of $94.3 million compared to a $100.6 million loss in 2022. Full commercial launch of the Platinum protein sequencer is expected in the first quarter. The company forecasts 2024 revenues of $3.7–$4.2 million.
Quanterix’s fourth quarter 2023 revenues declined 22.2% to $31.5 million. On a GAAP basis, revenues from Consumables, Accelerate Projects and Other rose 56%, 71% and 16% to account for 56%, 18%, and 12% of revenues, respectively. Instrument sales fell 39% to make up 10%, while Strategic Collaborations revenue was down 45% to represent 5%. Quanterix provides biomarker detection technology.
Full-year 2023 sales for Quanterix expanded 16.0% to $122.4 million. Consumables, Accelerator Projects, and other revenues rose 42%, 71% and 25% to make up 52%, 18% and 12% of sales, respectively. In contrast, Instruments and Strategic Collaborations revenues fell 37% and 45% to account for 13% and 5% of revenues, respectively. North American, European, and Asia Pacific sales grew 21.1%, 13.9% and 13.5% to represent 62%, 26% and 12% of revenues, respectively. Neurology applications were responsible for over 80% of revenues.
Quaterix’s 2024 sales are expected to gain 14%–18% to $139–$144 million. The company launched five new tests during 2023, including one LDT Test. In 2024 and beyond, it plans to launch at least 20 assays per year and complete an IVD test launch.
In March, Nuclera, the company enabling rapid protein expression and purification screening through its benchtop protein platform, announced the appointment of Joseph Bertelsen as CCO. He joins Nuclera from the Institute for Protein Innovation, a research institute focused on providing synthetic antibodies and protein expertise, where he was the Director of Commercialization.
Quantum-Si’s 2023 sales were $1.1 million compared to no revenues in the prior year (see Bottom Line). Adjusted EBITDA was a loss of $94.3 million compared to a $100.6 million loss in 2022. Full commercial launch of the Platinum protein sequencer is expected in the first quarter. The company forecasts 2024 revenues of $3.7–$4.2 million.
Quanterix’s fourth quarter 2023 revenues declined 22.2% to $31.5 million. On a GAAP basis, revenues from Consumables, Accelerate Projects and Other rose 56%, 71% and 16% to account for 56%, 18%, and 12% of revenues, respectively. Instrument sales fell 39% to make up 10%, while Strategic Collaborations revenue was down 45% to represent 5%. Quanterix provides biomarker detection technology.
Full-year 2023 sales for Quanterix expanded 16.0% to $122.4 million. Consumables, Accelerator Projects, and other revenues rose 42%, 71% and 25% to make up 52%, 18% and 12% of sales, respectively. In contrast, Instruments and Strategic Collaborations revenues fell 37% and 45% to account for 13% and 5% of revenues, respectively. North American, European, and Asia Pacific sales grew 21.1%, 13.9% and 13.5% to represent 62%, 26% and 12% of revenues, respectively. Neurology applications were responsible for over 80% of revenues.
Quaterix’s 2024 sales are expected to gain 14%–18% to $139–$144 million. The company launched five new tests during 2023, including one LDT Test. In 2024 and beyond, it plans to launch at least 20 assays per year and complete an IVD test launch.
In March, Nuclera, the company enabling rapid protein expression and purification screening through its benchtop protein platform, announced the appointment of Joseph Bertelsen as CCO. He joins Nuclera from the Institute for Protein Innovation, a research institute focused on providing synthetic antibodies and protein expertise, where he was the Director of Commercialization.
Product Introductions
In February, Revvity introduced the LabChip AAV empty/full characterization solution for streamlining gene therapy development and manufacturing.Bruker introduced in February the new ‘Triceratops’ SPR #64 instrument for the real-time, label-free biophysical characterization of molecular interactions. According to Bruker, the system combines the highest-sensitivity detection with a novel microfluidics concept, which via the perpendicular rotation of the eight-channel flow cell, facilitates the simultaneous reading of 64 sensor spots.
In February, Quantum-Si announced the release of new platform enhancements for its Platinum system, with the release of its new V2 Sequencing Kits. The assays include a new amino acid recognizer and an approximately three-fold reduction in cost per amino acid, according to the firm.
SPOC Proteomics announced in February the launch of beta testing for the SPOC (sensor-integrated proteome on a chip) biosensors. SPOC chips contain thousands of proteins on a single 1.5 cm2 chip. SPOC’s production method effectively reduces the cost of large-scale proteomic assays by 10–100x, according to the company.
In March, Nicoya Lifesciences launched flexible software configuration packages for its flagship Alto Digital Surface Plasmon Resonance (Digital SPR) system. The packages are designed to provide access to the Alto system at a cost-effective price. Users can choose between two software options, the Nicosystem Pro and Nicosystem Essentials, and add additional software application modules as needed. Additionally, Alto’s main consumable, the Alto Cartridge, is now offered at a lower price point to further drive down operating costs.
Laboratory Products
Consumables
Company Announcements
Chiron AS, a producer of chemical reference materials headquartered in Trondheim, Norway, announced in January the establishment in Trondheim of a research center dedicated to the enhanced surveillance of environmental pollutants, supported by an estimated NOK 40 million ($4 million) investment. The strategic relocation follows Chiron's acquisition by Antylia Scientific in July 2023 and its incorporation into the ZeptoMetrix operating division. The move to the new 18,837 ft2 (1,750 m2) premises aligns Chiron with Spex, NSI Laboratories and High Purity Standards in strengthening the ZeptoMetrix Reference Material and Proficiency Testing portfolio.Product Introductions
Savillex, a container and containment solutions provider, released in January a new PETG Square Media Bottle product line under its Purillex brand. The PETG bottles are manufactured in its US-based ISO Class 7 facility. Designed for use in critical life sciences applications, Purillex PETG Square Media Bottles are available both sterile and non-sterile in four sizes ranging from 125 mL to 1000 mL. They are produced through a combination of injection and stretch blow molding with the explicit intention of seamlessly replacing competing PETG media bottles. Savillex also has the capability to provide white label services to manufacturers seeking to use Purillex PETG bottles for their own branded product lines.Green Elephant Biotech announced in January its plant-based 96-well plate. The lifecycle of the well-plate generates 50% less CO? emissions than conventional polystyrene plates, according to the company. These savings are achieved using the plant-based plastic polylactic acid (PLA), which is obtained from corn starch. Green Elephant is the first company to produce disposable laboratory materials from PLA using injection molding. The Green Elephant 96-well plate will be available online and via distributors in a transparent, unsterilized version with a flat bottom.<
Sample Preparation
Product Introduction
In March, Waters announced the new Oasis WAX/GCB and GCB/WAX for PFAS Analysis Cartridges with newly designed features that significantly streamline and expedite sample preparation and analysis of PFAS, according to the company. Oasis WAX/GCB and GCB/WAX Cartridges are QC-tested by an accredited laboratory for low residual PFAS. The cartridges combine the two clean-up steps required under the US EPA’s Method 1633 for PFAS analysis, a weak anion-exchange (WAX) cartridge and dispersive SPE graphitized carbon black (GCB). They reduce the preparation process by approximately 30 minutes per sample batch, stated Waters.Lab Automation
Company Announcements
In January, Hudson Robotics and Art Robbins Instruments, a global laboratory automation solutions provider, and Argosy Healthcare Partners portfolio company, announced the appointment of Matt Tallman as Senior Vice President of Sales. He joins the company from Waters.Fiscal first quarter (ending December 31, 2023) sales for Azenta’s Sample Management Solutions (SMS) (consisting of sample & repository services, automated stores, cryogenic systems, automated sample tubes, and consumables and instruments) grew 5.3%, up 1% organically, to make up 51% of total company sales (see Bottom Line). Within the SMS business, Large Automated Stores revenue grew 37%, with Ziath adding $1 million in sales, and Sample Repository Solutions sales rose 7%. Excluding organic Consumables & Instruments (C&I) sales, SMS revenue rose 9%. C&I revenue grew 5% sequentially. For the fiscal year, SMS sales should expand with mid- to high single digit growth.
In January, Genie Life Sciences, a provider of laboratory workflow execution software, announced a partnership with Opentrons Labworks (Opentrons), a supplier of open-source liquid handling robots, for software solutions for operating Opentrons’ lab robots and modules. Pairing Genie LabOS with the Opentrons Flex or OT-2 allows for end-to-end instrument control, experiment planning and data management.
Also in January, Opentrons announced the launch of its automation marketplace with tools and software from Opentrons’ partners that can be easily integrated into Opentrons’ robotics systems. Opentrons’ automation marketplace features hardware, software and consumables coupled with user documentation and verified protocols. The first marketplace partners include research platform and technology companies Cerillo, maker of the Co-Culture Duet System for microbial studies, Genie Life Sciences, and microplate reader firm Byonoy.
In February, Opentrons announced the appointment of Gregory Cole, PhD, as Chief Innovation Officer. He served as CTO and Advisor at AiM Medical Robotics, where he was responsible for developing and manufacturing image-guided robotic surgical devices and R&D platforms.
In March, Opentrons announced the launch of Opentrons for Education, an exclusive offering for educators to bring lab automation to the classroom. It includes education pricing and support, along with access to a community of educators already teaching with Opentrons. Opentrons’ robots are already used in education settings at universities and research institutes, including MIT, Carnegie Mellon University, J. Craig Venter Institute, University College London, Colorado State University and Virginia Tech.
Beckman Coulter Life Sciences announced in January a strategic partnership with Polycarbin, a sustainable lab solutions company involving their respective automated liquid handling solutions and sustainability-focused circular economy platform for lab plastics. The two key objectives for the partnership in the US are: closed-loop recycling solutions and low-carbon lab products. The companies will imbue every product with third-party verified sustainability metrics.
Tech StartUps reported in February that Monomer Bio raised $5.6 million in seed funding, led by Talis Capital which was joined by LifeX, Notley Ventures and angels including Kevin Mahaffey and Amit Gupta. Monomer Bio integrates robotic lab automation with data management to execute experiments on a large scale and with greater complexity, such as cell engineering.
In February, SPT Labtech appointed Morten Frost Norgreen to the newly created position of CCO. He joins SPT Labtech from Veracyte, where he served as the CCO, IVD. SPT Labtech is a global manufacturer and designer of automated instruments and consumables for life science research with a focus on liquid handling, sample management and cryo-EM sample preparation technologies.
Also in February, SPT Labtech announced its continued partnership with the UK Health Security Agency (UKHSA) to advance global genomics surveillance. SPT Labtech deployed its automated liquid handling technology to the Oswaldo Cruz Foundation (FIOCRUZ) in Brazil, as part of the program facilitated through the New Variant Assessment Platform (NVAP) led by UKHSA. Two advanced liquid handling instruments, the mosquito HV genomics for multichannel positive displacement pipetting down to 500 nL and the dragonfly discovery for reliable non-contact reagent dispensing across all liquid types, were installed at FIOCRUZ to facilitate high-throughput sample preparation for genomic sequencing.
Beckman Coulter Life Sciences announced in January a strategic partnership with Polycarbin, a sustainable lab solutions company involving their respective automated liquid handling solutions and sustainability-focused circular economy platform for lab plastics. The two key objectives for the partnership in the US are: closed-loop recycling solutions and low-carbon lab products. The companies will imbue every product with third-party verified sustainability metrics.
Tech StartUps reported in February that Monomer Bio raised $5.6 million in seed funding, led by Talis Capital which was joined by LifeX, Notley Ventures and angels including Kevin Mahaffey and Amit Gupta. Monomer Bio integrates robotic lab automation with data management to execute experiments on a large scale and with greater complexity, such as cell engineering.
In February, SPT Labtech appointed Morten Frost Norgreen to the newly created position of CCO. He joins SPT Labtech from Veracyte, where he served as the CCO, IVD. SPT Labtech is a global manufacturer and designer of automated instruments and consumables for life science research with a focus on liquid handling, sample management and cryo-EM sample preparation technologies.
Also in February, SPT Labtech announced its continued partnership with the UK Health Security Agency (UKHSA) to advance global genomics surveillance. SPT Labtech deployed its automated liquid handling technology to the Oswaldo Cruz Foundation (FIOCRUZ) in Brazil, as part of the program facilitated through the New Variant Assessment Platform (NVAP) led by UKHSA. Two advanced liquid handling instruments, the mosquito HV genomics for multichannel positive displacement pipetting down to 500 nL and the dragonfly discovery for reliable non-contact reagent dispensing across all liquid types, were installed at FIOCRUZ to facilitate high-throughput sample preparation for genomic sequencing.
ABB Robotics, a robotic and machine automation supplier, and Mettler-Toledo announced in February that they signed a memorandum of understanding to offer a solution that seamlessly integrates ABB’s robots with LabX, Mettler-Toledo’s laboratory instrument management software. LabX software will integrate into ABB’s OmniCore robot controllers, enabling LabX to orchestrate robotic lab workflows. The collaboration is part of ABB’s ongoing strategy to bring the benefits of automation to new segments worldwide and complements the work at the life sciences and healthcare lab at the Texas Medical Center in Houston as well as the newly inaugurated Open Innovation Lab for Life Science and Healthcare in Zhangjiang Robot Valley, Shanghai.
In February, Eppendorf announced that Byonoy’s Absorbance 96 Automate on-deck absorbance plate reader, which features a compact footprint and fast readout, can be integrated into its epMotion liquid handling system.
In February, Opentrons announced the launch of its new protocol library, offering plug-and-play protocols for all Opentrons robots, including the Opentrons Flex. Along with the open-access protocol library, Opentrons created an AI-powered protocol generation tool that leverages large language models to allow users to create novel workflows for Opentrons robots. This endeavor aligns with other initiatives led by researchers at Carnegie Mellon University and MIT, aiming to create AI-driven lab assistants capable of designing and executing automated experiments utilizing Opentrons robots.
In February, Niryo, a collaborative robotics company, released Niryo Studio, calling it an application that simplifies the use of robots and offers a seamless user experience with connection and configuration of Niryo’s NED2 robot in just a few minutes. It is possible to connect all external devices linked to the robot and manage them from the application. The NED2 robot can be used for a wide range of applications, from programming practice to an introduction to AI and Industry 5.0 or to reproduce real-life work situations. The integrated Python IDE allows users to code directly in the Python language.
Azenta introduced in February the BioArc Ultra -80°, an automated solution for high-density ultracold large-scale sample management. The Ultra features eco-friendly cooling system utilizing natural air rather than manufactured, ozone-depleting refrigerants, enabling a zero-ozone depletion potential (ODP) and zero global warming potential (GWP). The refrigeration technology also reduces electric power consumption by 70% with a similar reduction in storage system footprint (compared to other commercially available manual options for similar storage capacity), according to the company. The system can store up to 16.92 million 0.9 mL tubes.
Product Introductions
In January, Eppendorf released the revised Enhanced Feature Set GxP software extension for its epMotion automated liquid handlers. The extension is designed to support customers operating in GxP environments and to achieve compliance with critical regulations such as 21 CFR Part11, EU GMP Annex 11 and GAMP 5.In February, Eppendorf announced that Byonoy’s Absorbance 96 Automate on-deck absorbance plate reader, which features a compact footprint and fast readout, can be integrated into its epMotion liquid handling system.
In February, Opentrons announced the launch of its new protocol library, offering plug-and-play protocols for all Opentrons robots, including the Opentrons Flex. Along with the open-access protocol library, Opentrons created an AI-powered protocol generation tool that leverages large language models to allow users to create novel workflows for Opentrons robots. This endeavor aligns with other initiatives led by researchers at Carnegie Mellon University and MIT, aiming to create AI-driven lab assistants capable of designing and executing automated experiments utilizing Opentrons robots.
In February, Niryo, a collaborative robotics company, released Niryo Studio, calling it an application that simplifies the use of robots and offers a seamless user experience with connection and configuration of Niryo’s NED2 robot in just a few minutes. It is possible to connect all external devices linked to the robot and manage them from the application. The NED2 robot can be used for a wide range of applications, from programming practice to an introduction to AI and Industry 5.0 or to reproduce real-life work situations. The integrated Python IDE allows users to code directly in the Python language.
Azenta introduced in February the BioArc Ultra -80°, an automated solution for high-density ultracold large-scale sample management. The Ultra features eco-friendly cooling system utilizing natural air rather than manufactured, ozone-depleting refrigerants, enabling a zero-ozone depletion potential (ODP) and zero global warming potential (GWP). The refrigeration technology also reduces electric power consumption by 70% with a similar reduction in storage system footprint (compared to other commercially available manual options for similar storage capacity), according to the company. The system can store up to 16.92 million 0.9 mL tubes.
Laboratory Equipment
Company Announcements
In January, Teledyne LABS announced it is now a major distributor of the Ecodyst evaporation systems. The principal users of Teledyne LABS chromatography instruments and Ecodyst benchtop rotary evaporator (rotavap) and large-scale evaporation systems include the pharmaceutical and agrichemical industries, contract laboratories, and academic and government research institutions. Ecodyst uses its technology for the efficient and gentle removal of solvent from samples.PHC’s fiscal nine-month (ending December 31, 2023) Biomedical (PHCbi) sales declined 9.3% to ¥39,823 million ($270 million), or 16% of total company revenues (see Bottom Line). This was mainly due to the decrease in demand for ultra-low temperature freezers for mRNA vaccine storage.
PHC, whose companies include lab equipment maker PHCbi, announced in February the appointment of Kyoko Deguchi as President, Representative Director and CEO, effective April 1. She succeeds Shoji Miyazaki. Ms. Deguchi currently serves as an independent external director of PHC Group and is Vice Director of Doya Orthopedic Rehabilitation. She has held a range of senior positions in finance and marketing in global healthcare companies such as Janssen Pharmaceuticals.
Xcell Biosciences (Xcellbio), a platform technology company focused on cell and gene therapy applications, announced in January a collaboration with ElevateBio, a technology platform company for gene and cell therapies. ElevateBio became the first member of Xcellbio’s beta program for its new AVATAR Foundry device. In addition, Michael Paglia, CTO at ElevateBio’s BaseCamp, joined Xcellbio’s Scientific Advisory Board. ElevateBio BaseCamp scientists will have access to Xcellbio’s AVATAR incubator system for cell therapy research and development as well as two new platforms: the AVATAR Ai system for measuring the potency of cell therapies and the AVATAR Foundry system for cGMP cell therapy manufacturing. The AVATAR and AVATAR Foundry systems are used to metabolically reprogram therapeutic cells to improve their potency and persistence in the tumor microenvironment (TME), while the AVATAR Ai provides real-time analysis of tumor cytotoxicity under TME conditions.
In February, Bioz, an AI software company, announced its partnership with V&P Scientific (V&P), a manufacturer of lab equipment and consumables. V&P’s products have been cited thousands of times by researchers around the world, with these mentions now being displayed within Bioz Badges on product pages throughout V&P’s website, along with a Content Hub, a standalone webpage for all V&P’s product citations.
Pipette maker INTEGRA Biosciences announced 2023 sales declined to CHF 157 million ($174 million) but were twice as high as before the pandemic. The number of employees increased to 573 with around 50 new jobs added. Also, during the year, the company integrated Ireland, Sweden and Denmark into its direct sales network and is planning to enter four more markets. During the year, INTEGRA Biosciences moved to a new campus in Zizers, Switzerland, increasing its indoor space by around 129,167 ft2 (12,000 m2). The new building includes a future production facility for pipette tips, which relocates part of production from the US to Switzerland.
BioLife Solutions’ Freezers and Thaw Systems platform revenue fell 34.9% to $11.4 million, and was down 32% excluding COVID-related revenue, to make up 35% of total company sales for the fourth quarter 2023. For the full year, Freezers and Thaw Systems platform sales dropped 22.6% to $51.6 million, and were down 20% excluding prior year COVID-related sales, to make up 36% of company revenue. The freezer product lines are in the process of being divested.
AGI Glassplant announced in January the launch of the AGI Glassplant Pilot Reactor Controller for easy control, automation and monitoring of any pilot reactor and associated devices via a single software interface. Using OPC Unified Architecture, this next generation reactor controller offers universal connectivity with a vast range of reactors and peripheral devices, including circulators, stirrers, sensors, and pumps, via a no-code software interface. AGI Glassplant provides a solution for every stage of the chemical processing journey.
In February, Thermo Fisher Scientific announced what it called a first-of-its-kind shelving system to increase the capacity of incubators using the four most-common cell culture production vessels. With the Thermo Scientific CultiMaxx shelving systems, the Thermo Scientific Heracell VIOS 250i and Thermo Scientific Forma Steri-Cycle i250 CO2 incubators can support up to a 150% increase of G-Rex bioreactors without compromising performance. The CultiMaxx System works with 1L or other cell culture bags; Thermo Scientific Nunc Cell Factory systems with 10 or 13 layers; Thermo Scientific Nunc Cell Factory systems with four layers; and G-Rex bioreactors from Wilson Wolf.
In February, Hamilton Company (Hamilton), an automated liquid handling systems provider, unveiled the Hamilton Pipetting Excellence Program (HPEP). The HPEP utilizes Hamilton’s automated liquid handling systems and technologies to monitor, validate and ensure quality pipetting from start to finish. The Hamilton Pipetting Excellence Program (HPEP) is comprised of three essential pillars: monitor, check (using the VeriPlate), and verify (field service engineers).
Elemental Machines, a data-driven laboratory and manufacturing operational connectivity company, announced in February the introduction of its Health Score predictive tool. The Health Score algorithm evaluates hidden patterns in both the power usage and temperature changes in lab freezers, providing a proactive approach to maintenance. By analyzing actual compressor and temperature patterns, and those of an ideal freezer, the tool can pinpoint irregularities that suggest a need for intervention—calibration, defrosting, or repair.
In February, PHC Corporation of North America (PHCNA), supplier of the PHCbi brand of cell preservation and growth products in the North America and Latin America markets, announced the release of a new model of PHCbi brand VIP ECO SMART ultra-low temperature (ULT) freezer series. The MDF-DU703VHA-PA is the first PHCbi brand ULT freezer to feature dual voltage capability, allowing laboratories to switch between 115V and 220V power sources.
In February, laboratory products manufacturer Starlab International (Starlab) introduced new models to its ErgoOne E multi-channel pipette series. The product family now includes five models to cover volumes 0.5 µL to 1250 µL in either eight or 12 channels. The new models are available now at a price of £897.74 ($1,139) for the eight-channel model and £1,047.91 ($1,330) for the 12-channel model.
In March, Starlab introduced Starlab Vortex Mixer. Features include the glove-compatible touchscreen user interface and sleep mode which reduces energy consumption by putting the device on standby after a period of unuse. Speed ranges from 300 rpm to 3500 rpm in touch mode.
Product Introductions
In January, lab equipment company Brand announced the availability of new eight- and 12-channel pipettes in its Transferpette electronic pipettes line in a 1250 uL nominal volume.AGI Glassplant announced in January the launch of the AGI Glassplant Pilot Reactor Controller for easy control, automation and monitoring of any pilot reactor and associated devices via a single software interface. Using OPC Unified Architecture, this next generation reactor controller offers universal connectivity with a vast range of reactors and peripheral devices, including circulators, stirrers, sensors, and pumps, via a no-code software interface. AGI Glassplant provides a solution for every stage of the chemical processing journey.
In February, Thermo Fisher Scientific announced what it called a first-of-its-kind shelving system to increase the capacity of incubators using the four most-common cell culture production vessels. With the Thermo Scientific CultiMaxx shelving systems, the Thermo Scientific Heracell VIOS 250i and Thermo Scientific Forma Steri-Cycle i250 CO2 incubators can support up to a 150% increase of G-Rex bioreactors without compromising performance. The CultiMaxx System works with 1L or other cell culture bags; Thermo Scientific Nunc Cell Factory systems with 10 or 13 layers; Thermo Scientific Nunc Cell Factory systems with four layers; and G-Rex bioreactors from Wilson Wolf.
In February, Hamilton Company (Hamilton), an automated liquid handling systems provider, unveiled the Hamilton Pipetting Excellence Program (HPEP). The HPEP utilizes Hamilton’s automated liquid handling systems and technologies to monitor, validate and ensure quality pipetting from start to finish. The Hamilton Pipetting Excellence Program (HPEP) is comprised of three essential pillars: monitor, check (using the VeriPlate), and verify (field service engineers).
Elemental Machines, a data-driven laboratory and manufacturing operational connectivity company, announced in February the introduction of its Health Score predictive tool. The Health Score algorithm evaluates hidden patterns in both the power usage and temperature changes in lab freezers, providing a proactive approach to maintenance. By analyzing actual compressor and temperature patterns, and those of an ideal freezer, the tool can pinpoint irregularities that suggest a need for intervention—calibration, defrosting, or repair.
In February, PHC Corporation of North America (PHCNA), supplier of the PHCbi brand of cell preservation and growth products in the North America and Latin America markets, announced the release of a new model of PHCbi brand VIP ECO SMART ultra-low temperature (ULT) freezer series. The MDF-DU703VHA-PA is the first PHCbi brand ULT freezer to feature dual voltage capability, allowing laboratories to switch between 115V and 220V power sources.
In February, laboratory products manufacturer Starlab International (Starlab) introduced new models to its ErgoOne E multi-channel pipette series. The product family now includes five models to cover volumes 0.5 µL to 1250 µL in either eight or 12 channels. The new models are available now at a price of £897.74 ($1,139) for the eight-channel model and £1,047.91 ($1,330) for the 12-channel model.
In March, Starlab introduced Starlab Vortex Mixer. Features include the glove-compatible touchscreen user interface and sleep mode which reduces energy consumption by putting the device on standby after a period of unuse. Speed ranges from 300 rpm to 3500 rpm in touch mode.
Electrochemistry
Company Announcements
DKK-TOA announced that its office in Bangkok, Thailand, began operations on February 1. DKK-TOA provides water quality analysis products.
Spectroscopy
Company Announcements
XRD company Stresstech announced that it signed an agreement with KmK Instrument which will take of Stresstech’s XRD products in Sweden, effective January 1. Per Lundin and Stress Service were the previous distributors and worked with Stresstech in Sweden since 2000.
In February, SciAps announced the launch of its new sales office in India. SciApps is an XRF and LIBS company.
Also in February, SciAps announced the opening of a new sales office in China. The new sales office will be a wholly owned foreign enterprise, a legal form attached to China's National Enterprise Law since 2020.
Color science and technology firm X-Rite, a Veralto company, announced the promotion of CFO Jeff McKee to President. X-Rite employs more than 800 people in 11 countries.
CDR FoodLab announced in February a distribution agreement with Benelux Scientific for Belgium, the Netherlands and Luxembourg. CDR FoodLab offers photometer-based systems for food and beverage QC.
High Q Technologies (High Q) announced in February a CAD 3.75 million ($2.8 million) Government of Canada investment through the Federal Economic Development Agency for Southern Ontario as part of the Regional Quantum Initiative. The funding will support the commercialization of the company’s EPR spectroscopy systems to study protein dynamics for use in pharma and biotech applications. In 2019, the government provided High Q with CAD 6.5 million ($4.8 million). The company is currently in beta testing and plans to launch its first system this year.
In February, Agilent Technologies announced the selection of Distinguished Professors Michel Barsoum and Yury Gogotsi at Drexel University and Professor Ananda Amarasekara at Prairie View A&M University as recipients of an Agilent Solutions Innovation Research Award (SIRA). The three honorees will receive separate awards for their research into materials to advance energy storage technology. The professors were recognized for their efforts to develop nanomaterials for battery/electrochemical energy storage applications, including the development and study of MXenes—a new class of 2D materials made from transition metals—which they co-discovered in 2011. Professor Barsoum’s award includes a one-year loan of an Agilent 8900 ICP-QQQ system. Professor Gogotsi’s award consists of a one-year loan of an Agilent 5900 ICP-OES system. Professor Amarasekara’s award consists of a one-year loan of an Agilent 7900 ICP-MS system. Agilent established the SIRA initiative in 2023 to stimulate innovative and impactful use of its products to help solve pressing scientific problems in academia.
Also in February, Thermo Fisher Scientific released the Thermo Scientific Nicolet Apex FTIR spectrometer, featuring the TE-MCT detector for faster data acquisition and higher signal-to-noise ratio compared to the previous model. The OMNIC Paradigm Software provides for easy operation. The new system replaces the Nicolet iS20 FTIR spectrometer.
In March, Applied Spectra introduced the compact, low-cost J200CX LIBS instrument. It incorporates a high repetition-rate laser and 3D stages for scanning over large sample areas with high spatial resolution. It also offers complete wavelength coverage. The portable system is designed to overcome the shortcomings of handheld LIBS for field applications, according to the company. Applied Spectra develops and manufactures laser ablation–based analysis systems.
In March, SciAps announced the Z-70 handheld LIBS system, designed for scrap sorting and metal fabrication shops. The laser eliminates the need to grind each piece of material before testing. The Z-70 uses a 6 mJ/pulse laser, which the company calls the most powerful in the LIBS sorting market.
Also in March, SciApps released the X-550 Geochem portable XRF system. It is designed for rugged, all-day testing and features an integrated fan that powers on when required to deliver high-duty cycle operations in the hottest of climates. The X-550 Geochem offers element suites through three selectable, automated X-ray source settings.
SciAps debuted in March its PowerHouse X, a portable benchtop XRF system. It features an 80 kV x-ray tube, specifically built to measure heavy rare early elements (REEs) such as terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er) and ytterbium (Yb) in the field.
Product Introductions
In February, Thermo Fisher Scientific introduced the new TruScan G3 Handheld Raman Analyzer for raw material identification for the pharmaceutical and biotech industries. The handheld device provides real-time, non-destructive identification of a broad range of chemical compounds. New features include a built-in touchscreen display and immersion probe for in situ testing.Also in February, Thermo Fisher Scientific released the Thermo Scientific Nicolet Apex FTIR spectrometer, featuring the TE-MCT detector for faster data acquisition and higher signal-to-noise ratio compared to the previous model. The OMNIC Paradigm Software provides for easy operation. The new system replaces the Nicolet iS20 FTIR spectrometer.
In March, Applied Spectra introduced the compact, low-cost J200CX LIBS instrument. It incorporates a high repetition-rate laser and 3D stages for scanning over large sample areas with high spatial resolution. It also offers complete wavelength coverage. The portable system is designed to overcome the shortcomings of handheld LIBS for field applications, according to the company. Applied Spectra develops and manufactures laser ablation–based analysis systems.
In March, SciAps announced the Z-70 handheld LIBS system, designed for scrap sorting and metal fabrication shops. The laser eliminates the need to grind each piece of material before testing. The Z-70 uses a 6 mJ/pulse laser, which the company calls the most powerful in the LIBS sorting market.
Also in March, SciApps released the X-550 Geochem portable XRF system. It is designed for rugged, all-day testing and features an integrated fan that powers on when required to deliver high-duty cycle operations in the hottest of climates. The X-550 Geochem offers element suites through three selectable, automated X-ray source settings.
SciAps debuted in March its PowerHouse X, a portable benchtop XRF system. It features an 80 kV x-ray tube, specifically built to measure heavy rare early elements (REEs) such as terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er) and ytterbium (Yb) in the field.
Informatics
Company Announcements
In February, LIMS firm LabWare announced the opening of an office in Seoul, South Korea.Collaborative Drug Discovery (CDD) announced in February it received a $300,000 grant from the Bill & Melinda Gates Foundation. The CDD Vault–hosted database generated through this grant provides foundational infrastructure to accelerate the selection of monoclonal antibodies against malaria. CDD Vault will provide the technology for the comparison and ranking of antibodies based on functional data. CDD Vault is used to manage chemical registration, structure-activity relationships (SAR) and securely scale collaborations.
In February, ENPICOM, a bioinformatics software solutions provider, announced a collaboration with Erasmus Medical Center, based in Rotterdam, the Netherlands. The aim of the partnership is to identify and develop nanobodies against cancer by utilizing ENPICOM’s immune repertoire data analysis services and software solutions. The collaboration is funded by the Ministry of Economic Affairs.
Cresset, a provider of integrated in silico solutions for drug discovery, announced in February a collaboration with Enamine, a provider of chemical building blocks and drug discovery services. The collaboration involves the development of technology to enable the screening of ultra-large chemical spaces as part of the virtual screening process in drug discovery. Ignite is a form of virtual screening technology developed by Cresset that utilizes knowledge of the construction of these ultra-large chemical spaces, in terms of reagents as synthons and reactions, that allows the rapid screening of the space. The technology has been successfully applied to Enamine’s REAL Space, a library of over 38 billion make-on-demand molecules, and currently the largest collection of commercially available compounds, according to the companies.
In February, LIMS firm LabVantage Solutions announced a significant expansion of its Professional Services Organization. Now operational globally, with new teams in South America and Asia, the organization has grown over 80% over the past three years (2020-2023).
In March, Biosero, a developer of laboratory automation solutions to orchestrate scientific discoveries, announced the appointment of Daniel Schumann as COO. Prior to joining Biosero, Mr. Schumann served as vice president of operations at Becton, Dickinson, and Company, where he led a center of excellence focusing on medical instrument manufacturing and new product introduction.
Product Introductions
In March, Genedata, a provider of enterprise software solutions for biopharmaceutical R&D, announced a new release of Genedata Screener, its enterprise platform for automated assay data analytics and consolidated assay information management across an enterprise. The new version features a new module, Assay Performance Monitoring, which Genedata calls the first commercially available solution for monitoring assay data quality in the context of historical data. With this release, Screener now enables a fully automated and unattended workflow starting with data capture and concluding with reporting of the results to a data warehouse. The new version also integrates an AI-based classifier that automates the classification of binding profiles produced by SPR and biolayer interferometry (BLI) measurements.In February, QIAGEN released the QIAGEN Biomedical KB-AI, a new generative AI-driven knowledge base designed for drug discovery. QIAGEN Biomedical KB-AI is built on a massive dataset of biomedical literature and other scientific sources. It identifies and extracts causal relationships between genes, diseases, drugs, and other biological entities with AI, generating over 600 million more biomedical relationships than its complement, QIAGEN Biomedical KB-HD. While QIAGEN Biomedical KB-HD is manually curated and known for its high quality and accuracy, QIAGEN Biomedical KB-AI contains over 25x more relationships.
In February, Optibrium, a developer of software and AI solutions for drug discovery, introduced Semeta, a metabolism prediction platform tailored specifically for drug metabolism and pharmacokinetics (DMPK) scientists. Semeta enables more precise metabolite prediction across the key enzymes involved in human Phase I and II metabolism, according to the company. It also includes models for rat, mouse, and dog cytochrome P450 (CYP). This enables comparison between human, rat, mouse, and dog predictions, supporting selection of the most appropriate preclinical species for in vivo efficacy, PK, and toxicology studies.
In February, Metabolon, a provider of metabolomics solutions, announced the launch of an integrated bioinformatics platform featuring a database of more than 5,400 biologically relevant metabolites. The platform seamlessly integrates a comprehensive suite of tools and features including pathway analysis; the Biomarker Lenses, advanced analytical filters to enhance the exploration of metabolomic data by focusing on metabolites associated with specific pathways and disease; and principal component analysis (PCA).
Broad-Based Companies
Company Announcements
Sartorius’ 2023 Bioprocess Solutions (BPS) sales declined 15.4%, down 17.6% in constant currency, to €2,678.2 million ($2,911.1 million) to make up 79% of total company revenues. BPS underlying EBITDA fell 34.2% to €782.3 million ($850.3 million). In 2024, division sales are forecast to expand mid- to high single-digits including a two-percentage-point contribution from acquisitions. The company expect the destocking situation to mostly resolve itself by mid-year. Sartorius’ mid-term outlook to 2028 puts BPS growth in the low to mid-teens CAGR.Sartorius announced in its 2023 annual report that in June 2023 it acquired Turkey-based Sartonet Seperasyon Teknolojileri, a distributor and service provider with 40 employees.
In February, HORIBA announced its new Mid-Long Term Management Plan (MLMAP2028), stating its net sales target of ¥450 billion ($2,992 million) by 2028. This would result in a 2023–28 CAGR of 9.1%. The company also announced three focus field: Energy & Environment, Bio & Healthcare, and Materials & Semiconductor, with respective 2028 financial targets of ¥158.0 billion ($1,050 million), ¥57.0 billion ($379 million) and ¥235.0 billion ($1,562 million). 2024 sales for the respective focus fields are expected to be ¥130 billion ($864 million), ¥40 billion ($266 million), and ¥151 billion ($1,004 million). Within the respective markets, HORIBA plans “new business” sales by 2028 to reach ¥31 billion ($206 billion) for new energy, ¥14 billion ($93 billion) for life science and ¥15 billion ($99 million) for the semiconductor industry.
In 2023, Spectris Scientific (Malvern Panalytical, Particle Measuring Systems) sales grew 7.1%, 12% on a like-for-like basis (LFL) to £704.28 million ($880.35 million), to represent 40% company revenues. By end-market for the total company on LFL basis, life sciences/pharmaceutical sales declined 9% to make up 18% of revenues, technology-led industrials revenue rose 8% to represent 16%, electronics and semiconductor sales grew 19% to make up 12%, automotives sale increased 8% to make up 10%, materials revenue grew 16% to account for 10%, academic research revenue increased 29% to make up 10%, and other sales rose 19% to account for 24%. Adjusted operating profit for Spectris Scientific rose 10.9%, 13% LFL, to £155.2 million ($194.0 million).
Regarding Spectris Scientific’s 2023 particle characterization revenue, laser diffraction sales were good for small molecule R&D, especially in the India and North America, but biologics sales for nanometrics were lower after a strong performance in the prior two years. The division’s primary materials sales were led by Asia and driven by mining and minerals applications, including x-ray system demand and sales for petrochemical, polymer and building materials customers. Demand from the segment’s advanced materials customers also showed increases as XRD sales grew, particularly in China. In the first half of the year, XRD demand was also strong from academic and research organizations for materials research and the analysis of batteries.
Repligen announced in March the appointment to its Board of Maggie A. Pax. Her experience includes eight years with Thermo Fisher Scientific, where, from 2016 to 2020, she served as Vice President, Strategy, and Innovation for the clinical supply chain business. This appointment expands the size of Repligen’s Board from eight to nine members. Repligen is a life sciences company that develops and commercializes bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.
Veralto, a technology solutions firm, reported that 2023 core sales for analytical instrumentation grew 3.2% and were driven by municipal and industry users. The fourth quarter 2023 marked the third quarter of sequential increase for water analytics sales in China.
Bruker announced in March the closing of its acquisition of Chemspeed Technologies (Chemspeed). Buker expects Chemspeed be near break-even for the remaining three quarters of the year, with approximately $10 million of revenue per quarter, as it transitions to US GAAP reporting and aligns with Bruker’s revenue recognition policies. By 2025, Chemspeed is expected to be $0.02–$0.03 accretive to Bruker’s non-GAAP EPS. Going forward, Chemspeed revenue is expected to grow high single digit to low double digits on an organic basis.
In March, Rigaku announced the opening of its new Rigaku Taiwan Branch. Additional plans are underway to establish the Rigaku Taiwan Technical Center. The center will feature demonstration facilities and laboratories.
Bioz, an AI company specializing in the analysis of scientific literature, announced in March its partnership with Teledyne LABS, which consists of CETAC, Hanson, ISCO chromatography and pumps, Leeman Labs and Tekmar brands. Visitors to the Teledyne LABS website will be able to view product citation data for individual products directly on Teledyne LABS’ webpages through Bioz Badges.
In March, Eppendorf announced that it received the ACT label for three more product groups, the Multipette M4 multi-dispenser, the ThermoMixer C and the recently launched Mastercycler X40, adding to the more than 150 of its products with the label. My Green Lab's ACT (Accountability, Consistency, and Transparency) labels function similarly to nutrition labels, providing a comprehensive evaluation of sustainability-related aspects.
Bio-Rad Laboratories announced in March that Roop K. Lakkaraju will join the company as its new Executive Vice President and CFO, effective April 15. He comes to Bio-Rad from Benchmark Electronics, a multinational electronics manufacturing services, where he served as Executive Vice President and CFO responsible for all finance-related functions supporting the company’s global operations since 2018.
Repligen announced in March the appointment to its Board of Maggie A. Pax. Her experience includes eight years with Thermo Fisher Scientific, where, from 2016 to 2020, she served as Vice President, Strategy, and Innovation for the clinical supply chain business. This appointment expands the size of Repligen’s Board from eight to nine members. Repligen is a life sciences company that develops and commercializes bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.
Veralto, a technology solutions firm, reported that 2023 core sales for analytical instrumentation grew 3.2% and were driven by municipal and industry users. The fourth quarter 2023 marked the third quarter of sequential increase for water analytics sales in China.
Bruker announced in March the closing of its acquisition of Chemspeed Technologies (Chemspeed). Buker expects Chemspeed be near break-even for the remaining three quarters of the year, with approximately $10 million of revenue per quarter, as it transitions to US GAAP reporting and aligns with Bruker’s revenue recognition policies. By 2025, Chemspeed is expected to be $0.02–$0.03 accretive to Bruker’s non-GAAP EPS. Going forward, Chemspeed revenue is expected to grow high single digit to low double digits on an organic basis.
In March, Rigaku announced the opening of its new Rigaku Taiwan Branch. Additional plans are underway to establish the Rigaku Taiwan Technical Center. The center will feature demonstration facilities and laboratories.
Bioz, an AI company specializing in the analysis of scientific literature, announced in March its partnership with Teledyne LABS, which consists of CETAC, Hanson, ISCO chromatography and pumps, Leeman Labs and Tekmar brands. Visitors to the Teledyne LABS website will be able to view product citation data for individual products directly on Teledyne LABS’ webpages through Bioz Badges.
In March, Eppendorf announced that it received the ACT label for three more product groups, the Multipette M4 multi-dispenser, the ThermoMixer C and the recently launched Mastercycler X40, adding to the more than 150 of its products with the label. My Green Lab's ACT (Accountability, Consistency, and Transparency) labels function similarly to nutrition labels, providing a comprehensive evaluation of sustainability-related aspects.
Bio-Rad Laboratories announced in March that Roop K. Lakkaraju will join the company as its new Executive Vice President and CFO, effective April 15. He comes to Bio-Rad from Benchmark Electronics, a multinational electronics manufacturing services, where he served as Executive Vice President and CFO responsible for all finance-related functions supporting the company’s global operations since 2018.
2023 sales for Judges Scientific, whose business include some analytical instruments companies, grew 20.2%, 15% on an organic basis, to £136.1 million ($170.1 million) (see Bottom Line). Materials Science sales increased 21.0% to account for 53% of revenues. Vacuum sales grew 19.2% to make up 47%. Adjusted operating profit increased 15.6% to £34.8 million ($43.5 million). By region, North America, Rest of Europe, Rest of World, China/Hong Kong, Rest of World and UK revenues increased 18.8%, 4.3%, 44.0%, 32.4% and 10.5% to represent 28%, 25%, 23%, 14% and 11% of revenues. The US, Taiwan, South Korea, and Japan were highlights, while sales in Germany and Czech Republic declined. Among Judges Scientific companies are analytical instrument and aftermarket companies are Deben, which provides solutions for SEM and µX-Ray CT in-situ tensile testing, and SEM detectors and accessories; Oxford Cryosystems, which manufactures open flow cryocoolers for the XRD market; Quorum Technologies, which supplies electron microscopy sample preparation solutions; and Scientifica, which offers nanopositioning, photomanipulation and advanced imaging systems.
In March, the North Carolina Collaboratory—an organization dedicated to advancing scientific research for policymaking within North Carolina —announced its partnership with Thermo Fisher Scientific to advance the state’s PFAS research capabilities. Supported by appropriations from the North Carolina General Assembly (NCGA), the Collaboratory purchased five mass spectrometers. To address this potential risk of PFAS contamination, the Water Safety Act included in the state’s 2018 budget provided the Collaboratory with its first appropriation of $5 million to establish the NC PFAS Testing Network (PFAST Network) to comprehensively document PFAS contamination across the State and better understand its impacts on the environment and public health. Currently, the Network includes researchers from eight campuses—ECU, FSU, NCA&T, NCCU, NCSU, UNC-CH, UNCC, UNCW and Duke—who study PFAS toxicology, occurrence in drinking water, atmospheric transformations and occurrence, and removal technologies. As of July 1, PFAS funding from the NCGA will eclipse $50 million (which includes additional Water Safety Act appropriations in subsequent NCGA budgets). In its entirety, this investment represents the largest legislative funding commitment for PFAS academic research in the nation. The Thermo Fisher instruments that will be acquired are: the new Orbitrap Astral MS system in Professor Lee Ferguson’s lab at Duke University, which will allow the first fully comprehensive analysis of known and unknown PFAS in environmental samples at ultra-trace levels, according to the announcement; the Orbitrap Exploris GC systems in Professor Heather Stapleton’s (Duke) and Professor Detlef Knappe’s (NCSU) labs, which will allow for the detection of semi-volatile PFAS in the indoor environment and volatile thermal breakdown products of PFAS treatment technologies; the Orbitrap Exploris 240 Isotope Solutions system in Professor Ralph Mead’s lab at UNC-Wilmington, which will enable source-tracing and high-resolution forensic analysis of PFAS in the environment; and the iCAP-TQ ICP-MS in Professor Pingping Meng’s lab at ECU, which will facilitate the development of new and sensitive total PFAS measurements for mass balance studies during PFAS treatment experiments.
In March, the North Carolina Collaboratory—an organization dedicated to advancing scientific research for policymaking within North Carolina —announced its partnership with Thermo Fisher Scientific to advance the state’s PFAS research capabilities. Supported by appropriations from the North Carolina General Assembly (NCGA), the Collaboratory purchased five mass spectrometers. To address this potential risk of PFAS contamination, the Water Safety Act included in the state’s 2018 budget provided the Collaboratory with its first appropriation of $5 million to establish the NC PFAS Testing Network (PFAST Network) to comprehensively document PFAS contamination across the State and better understand its impacts on the environment and public health. Currently, the Network includes researchers from eight campuses—ECU, FSU, NCA&T, NCCU, NCSU, UNC-CH, UNCC, UNCW and Duke—who study PFAS toxicology, occurrence in drinking water, atmospheric transformations and occurrence, and removal technologies. As of July 1, PFAS funding from the NCGA will eclipse $50 million (which includes additional Water Safety Act appropriations in subsequent NCGA budgets). In its entirety, this investment represents the largest legislative funding commitment for PFAS academic research in the nation. The Thermo Fisher instruments that will be acquired are: the new Orbitrap Astral MS system in Professor Lee Ferguson’s lab at Duke University, which will allow the first fully comprehensive analysis of known and unknown PFAS in environmental samples at ultra-trace levels, according to the announcement; the Orbitrap Exploris GC systems in Professor Heather Stapleton’s (Duke) and Professor Detlef Knappe’s (NCSU) labs, which will allow for the detection of semi-volatile PFAS in the indoor environment and volatile thermal breakdown products of PFAS treatment technologies; the Orbitrap Exploris 240 Isotope Solutions system in Professor Ralph Mead’s lab at UNC-Wilmington, which will enable source-tracing and high-resolution forensic analysis of PFAS in the environment; and the iCAP-TQ ICP-MS in Professor Pingping Meng’s lab at ECU, which will facilitate the development of new and sensitive total PFAS measurements for mass balance studies during PFAS treatment experiments.
MyBio announced a new exclusive partnership with QIAGEN to distribute QIAGEN’s Life Science “Sample to Insight” product range throughout Ireland and Northern Ireland with effect from April 1.
Bioprocess Analysis
Company Announcements
Miltenyi Biotec, a provider of products and services for biomedical research and cellular therapy, and Replay, a genome writing company reprogramming biology by writing, designing, and delivering big DNA, announced in December 2023 a licensing and manufacturing agreement to support the development of a GMP-compliant T-cell receptor (TCR) natural killer (NK) cell therapy targeting the tumor-associated neoantigen, PRAME. Syena, the oncology-focused engineered cell therapy product company launched jointly by Replay and the University of Texas MD Anderson Cancer Center in February 2023, secured an exclusive license to Miltenyi Biotec’s PRAME (PReferentially expressed Antigen in MElanoma) TCR. Miltenyi Biotec will use its CliniMACS Prodigy closed and automated cell processing platform to manufacture a scalable, GMP-compliant, PRAME-targeted, TCR-NK cell therapy product for clinical development and provision of future commercial supply.In January, INFORS HT announced that it named Paul Orange as CCO. He most recently served as CCO Officer & Board member at calorimeter company H.E.L Group. INFORS HT specializes in bioreactors, shaker incubators, and bioprocess control software.
Scientific Industries (SI), a life sciences tool provider and a developer of digitally simplified bioprocessing products, announced in January the closing of an approximately $7.0 million private placement financing. The company intends to use the net proceeds from this offering for the further development, commercialization, and marketing of products for bioprocessing on the DOTS Platform of the company’s Bioprocessing segment (which operates under its Scientific Bioprocessing (SBI) and aquila biolabs subsidiaries), and for general corporate purposes.
In March, SI announced the appointment of John Nicols to the Board of SI and Chairman of SBI, Mr. Nicols, who replaces Mr. John A. Moore as Chairman of SBI, is the former president and CEO of synthetic biology company Codexis.
In January, Stämm, a bioprocessing technology company, announced the opening of its new R&D facility in Monthey, Switzerland. The firm has over 200 employees in Buenos Aires, Argentina, and San Francisco, California.
In February, 908 Devices, a provider of purpose-built handheld and desktop devices for chemical and biochemical analysis, and Cellares, which calls itself the first integrated development and manufacturing organization (IDMO) dedicated to clinical and commercial-scale cell therapy manufacturing, announced a development collaboration to integrate in-line monitoring of key cell culture parameters into Cellares’ Cell Shuttle system, a fully integrated, scalable, cell therapy manufacturing platform. 908 Devices is integrating its optical in-line analyzer, MAVERICK, which according to the firm is the first turn-key device to utilize Raman spectroscopy for bioprocess control, with no modeling or development required.
In March, the Cultivated B (TCB) announced the name change of its Canadian subsidiary. Formerly called the Cultivated B Canada, it is now known as n!Biomachines n!Biomachines delivers affordable, easy-to-operate systems for the food, dietary supplement and cosmetics industries¸ according to the firm.
BIONT, a company in Taiwan’s regenerative medicine field, announced in March the successful integration of Univercells Technologies’ scale-X fixed-bed bioreactor. Utilizing the scale-X hydro system, BIONET aims to enhance the production of extracellular vesicles produced by mesenchymal stem cells (MSCs) for clinical use. Univercells Technologies by Donaldson is a provider of biomanufacturing technologies to achieve cost-effective viral production from R&D to commercial scales.
Eurofins’ Alphora business, a CDMO based in Mississauga, Canada, announced the successful completion of its pilot-scale biologics development facility. Spanning 3,300 ft2 (307 m2), the facility is dedicated to the development and scaling of mAbs and other mammalian-based therapeutic proteins. The facilities’ offerings include upstream and downstream development, process design, analytical development, GMP QC testing, GMP cell-based assays, and scale-up capacity to 200 L for pre-clinical and phase I supply. It leverages equipment, such as the Sartorius Amber 250 bioreactor and Nova Biomedical’s BioProfile FLEX2 Automated Cell Culture Analyzer.
Product Introductions
In March, ArgusEye, a provider of sensor solutions for real-time monitoring of biological systems, announced the release of the AugaOne sensor system. AugaOne is the first product in the company’s sensor system platform, Auga, and is tailored to accelerate downstream mAb process development by providing specific real-time and automated in-line data with high sensitivity, without requiring sample pretreatment, stated the company. Utilizing a nanoplasmonic sensing technology platform, AugaOne offers specific real-time monitoring of critical quality attributes and process parameters to determine the optimal process. Adapted for downstream processing, AugaOne facilitates applications such as in-line detection of product breakthrough, as well as the automated control of a multi-column chromatography setup.Sales & Orders of Note
KaliVir Immunotherapeutics, a biotech company developing multi-mechanistic oncolytic viral immunotherapy programs, unveiled in February its GMP cleanroom facility to manufacture its pipeline of oncolytic viruses. The manufacturing facility includes a cleanroom spanning over 1,000 ft2 (93 m2). The facility is equipped with the iCellis 500 bioreactor from Cytiva, and hyperstack, filtration and chromatography capabilities.Eurofins’ Alphora business, a CDMO based in Mississauga, Canada, announced the successful completion of its pilot-scale biologics development facility. Spanning 3,300 ft2 (307 m2), the facility is dedicated to the development and scaling of mAbs and other mammalian-based therapeutic proteins. The facilities’ offerings include upstream and downstream development, process design, analytical development, GMP QC testing, GMP cell-based assays, and scale-up capacity to 200 L for pre-clinical and phase I supply. It leverages equipment, such as the Sartorius Amber 250 bioreactor and Nova Biomedical’s BioProfile FLEX2 Automated Cell Culture Analyzer.
Process Analysis
Company Announcements
Tibidabo Scientific Industries (Tibidabo), a provider of technology for scientific research, aerospace, and industrial markets, announced in November 2023 the acquisition of LLA Instruments (LLA), a manufacturer of products that support industrial sorting, QC, and various applications in atomic emission spectroscopy (AES) and LIBS. LLA uses NIR measurement technology with analysis and classification software that aids in the detection and identification of different materials at industrial scale from recycle sorting, and mineral and elemental analysis to food and feed, functional coating, and refuse-derived fuel analysis.In January, Thorlabs, a manufacturer of photonics products, entered into a licensing and technology transfer agreement to expand the existing mid-IR spectroscopic sensing platform developed at IRsweep into additional applications. Thorlabs will leverage IRsweep's quantum cascade laser–based dual-frequency-comb spectroscopy instruments to develop a sensing platform that combines the strengths of conventional broadband spectroscopy and tunable laser spectroscopy into one device. This will enable Thorlabs to offer a tool for a wide range of applications, including gas sensing, environmental monitoring, and chemical analysis.
Product Introductions
In February, Yokogawa Corporation of America (Yokogawa) introduced the TDLS8220 extractive tunable diode laser spectrometer (TDLS), a new generation OpreX Analyzer product. This product joins Yokogawa’s existing lineup that includes the in-situ TDLS8000 and probe-type TDLS8100/TDLS8200. The TDLS8220 is a direct replacement for the first-generation TDLS220.In March, Metrohm Process Analytics introduced the 2060 Raman Analyzer in-line process analyzer. The 2060 Raman Analyzer can measure up to five sampling points hundreds of meters away. It has two embedded software products, the IMPACT software, and the Vision software. Also, it is compatible with all Metrohm instruments, data, and spectrum libraries. Results are available in less than 10 seconds.
Sequencing
Company Announcements
The US Congress in January the BIOSECURE Act, which would ban government executive agencies from doing business with or providing loan or grants to companies with commercial agreements for biotech equipment or service from Chinese sequencer maker MGI Tech (MGI) as well as related US firm Complete Genomics, among other Chinese companies. The bill is intended to limit Chinese government access to US genomic data. In a February letter to US customers, Complete Genomics asserted that the company is founded and based in the US; is not a sequencing service provider and does not have access to, collect, or maintain genetic data; and that its sequencers in not connected to its servers and none of lab’s DNA data is shared with it. It stated that any information created or maintained users is done by the customers who maintain sole control and responsibility for safeguarding the privacy of the data they generate. Complete Genomics also stated that it is independent of BGI Tech, which was previously sanctioned by the US government, with its own structure and government and that it is no longer a subsidiary.In March, MGI, a company committed to building core tools and technology to lead life science, announced a milestone collaboration with Eurofins Genomics Europe Genotyping A/S (Eurofins Genomics), which has placed a corporate order for the DNBSEQ-T20×2 (T20) ultra-high throughput sequencer, along with the genomics data center ZTRON Appliance and a range of MGI's laboratory automation products and systems. This marks the first corporate order of the T20 in the Europe region. Eurofins Genomics offers specialty esoteric and molecular clinical diagnostic testing in Europe and the US.
In February, Standard BioTools, a life science tools firm, and Next Gen Diagnostics (NGD) announced the execution of a long-term agreement. Under the exclusive agreement, Standard BioTools will manufacture the NGD-100, a version of its microfluidics-based Biomark X9 System customized for NGD and optimized for automated pathogen whole genome sequencing library preparation. The solution combines Standard BioTools’ microfluidic liquid handling system with NGD’s automated pathogen bioinformatics, enabling NGD to offer integrated pathogen sequencing and bioinformatic services with the rapid turnaround and low cost required for large-scale impact on infection control and ultimately on clinical microbiology, according to the firms. NGD offers integrated high-volume turn-key sequencing and bioinformatic services to enable detection of transmission in hospitals.
In March, Armonica Technologies announced the appointment of Tood Dickinson to its Board. He currently serves as CEO of Stellaromics, a company developing 3D in situ multi-omic analysis technology.
Oxford Nanopore Technologies (Oxford Nanopore), a nanopore-based molecular sensing technology firm, announced the retirement of three Directors from its Board: Chief Strategy Officer Dr. James ("Spike") Willcocks; Clive Brown, Chief Technology, Innovation and Product Officer; and COO Tim Cowper. Mr. Brown will step down with immediate effect, while Dr. Willcocks and Mr. Cowper will retire from the Board at the conclusion of the annual general meeting in June. All three Directors will remain in their operational leadership roles at Oxford Nanopore, and each will also continue to serve on the company's Operating Committee.
In March, Oxford Nanopore and SeqOne, which provides AI-driven genomic decision support software, announced a new partnership enabling end-to-end analytical workflows from sample to report, focusing on rare diseases in the short term and oncology in the longer term. Available today on Oxford Nanopore’s SeqOne’s platform, the germVar applications enables AI-enhanced whole genome variant interpretation from Oxford Nanopore EPI2ME, currently for RUO.
In March, Element Biosciences, a developer of sequencer technology, announced the appointment of Danae Van Oene as Senior Vice President of Global Sales and Support. She was most recently 10x Genomics’ Vice President and General Manager for the Americas region.
Fabric Genomics (Fabric), a provider of solutions for AI-powered NGS interpretation, announced in March a new partnership with Intermountain Children’s Health to analyze the whole genomes of children sequenced by the Broad Clinical Labs to help speed diagnosis of kids who may have genetic diseases. The whole genome sequencing service from Broad Clinical Labs utilizes GEM, Fabric’s AI algorithm, a tool that can more precisely detect CNVs and detect causative SNPs and smaller CNVs that are invisible to commonly used microarray genetic tests, according to the company.
In March, Alithea Genomics (Alithea) announced the closing of a CHF 2.8 million ($3.2 million) extension to its seed financing. The round was led by the Novalis Biotech Acceleration Fund and included new investor TechU Ventures alongside existing investors. The proceeds will be used to continue commercialization and expand manufacturing capacity of Alithea’s RNA sequencing products, advance the development of new technologies and establish a subsidiary in the US. Alithea commercializes massively multiplexed library preparation solutions for RNA sequencing, most notably BRB-seq and DRUG-seq. These technologies enable the preparation of hundreds of RNA samples for sequencing in a single tube and, in the case of DRUG-seq, without the need for RNA isolation.
Oxford Nanopore Technologies (Oxford Nanopore), a nanopore-based molecular sensing technology firm, announced the retirement of three Directors from its Board: Chief Strategy Officer Dr. James ("Spike") Willcocks; Clive Brown, Chief Technology, Innovation and Product Officer; and COO Tim Cowper. Mr. Brown will step down with immediate effect, while Dr. Willcocks and Mr. Cowper will retire from the Board at the conclusion of the annual general meeting in June. All three Directors will remain in their operational leadership roles at Oxford Nanopore, and each will also continue to serve on the company's Operating Committee.
In March, Oxford Nanopore and SeqOne, which provides AI-driven genomic decision support software, announced a new partnership enabling end-to-end analytical workflows from sample to report, focusing on rare diseases in the short term and oncology in the longer term. Available today on Oxford Nanopore’s SeqOne’s platform, the germVar applications enables AI-enhanced whole genome variant interpretation from Oxford Nanopore EPI2ME, currently for RUO.
In March, Element Biosciences, a developer of sequencer technology, announced the appointment of Danae Van Oene as Senior Vice President of Global Sales and Support. She was most recently 10x Genomics’ Vice President and General Manager for the Americas region.
Fabric Genomics (Fabric), a provider of solutions for AI-powered NGS interpretation, announced in March a new partnership with Intermountain Children’s Health to analyze the whole genomes of children sequenced by the Broad Clinical Labs to help speed diagnosis of kids who may have genetic diseases. The whole genome sequencing service from Broad Clinical Labs utilizes GEM, Fabric’s AI algorithm, a tool that can more precisely detect CNVs and detect causative SNPs and smaller CNVs that are invisible to commonly used microarray genetic tests, according to the company.
In March, Alithea Genomics (Alithea) announced the closing of a CHF 2.8 million ($3.2 million) extension to its seed financing. The round was led by the Novalis Biotech Acceleration Fund and included new investor TechU Ventures alongside existing investors. The proceeds will be used to continue commercialization and expand manufacturing capacity of Alithea’s RNA sequencing products, advance the development of new technologies and establish a subsidiary in the US. Alithea commercializes massively multiplexed library preparation solutions for RNA sequencing, most notably BRB-seq and DRUG-seq. These technologies enable the preparation of hundreds of RNA samples for sequencing in a single tube and, in the case of DRUG-seq, without the need for RNA isolation.
Bioinformatics provider MENADNA announced in March that it entered an exclusive partnership with ProPhase Labs' subsidiary Nebula Genomics aiming to advance genomic testing in Jordan, Oman, and Iraq. This collaboration will leverage Nebula Genomics' advanced sequencing technologies and MENADNA's bioinformatics capabilities.
Singular Genomics’ full-year 2023 revenues increased 280.5% to $2.9 million (see Bottom Line) with a cumulative 24 systems shipped. Single Genomics develops sequencing and multi-omics technologies.
In March, SPT Labtech, a designer, developer and manufacturer of automated instrumentation and consumables for life science applications, announces a co-marketing collaboration with Roche to deliver a streamlined method for Illumina-compatible NGS library preparation. By leveraging SPT Labtech’s all-in-one automated liquid handling platform, firefly, this collaboration offers genomics researchers fully automated workflows for Roche’s KAPA EvoPlus and KAPA EvoPlus PCR-Free Kits The agreement covers RUO and diagnostic procedures.
Bayer and Thermo Fisher Scientific announced in March a collaboration to develop NGS-based companion diagnostic assays (CDx) together. The CDx will be developed using Thermo Fisher’s Oncomine Dx Express Test on the Ion Torrent Genexus Dx System, a fully integrated NGS platform that can deliver results on a patient’s tumor or liquid biopsy sample in as little as 24 hours.
In March, Fluent BioSciences (Fluent), a life sciences company providing what it calls simple, cost-effective, and highly scalable single-cell RNA sequencing solutions, announced the award of an NIH Small Business Innovation Research (SBIR) Phase II grant, funded by the National Institute of General Medical Sciences. This funding will support the commercialization of million-cell analysis kits enabled by low-cost, high-capacity sequencing by Ultima Genomics.
SOPHiA GENETICS’ fourth quarter 2023 revenues increased 27.4% to $17.0 million (see Bottom Line). In constant currency excluding COVID-19 related revenues, sales grew 26.9%. Adjusted operating loss expanded from $12.1 million to $13.3 million. The company signed 35 new core genomics customers during the quarter. SOPHiA GENETICS is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research.
2023 revenues for SOPHiA GENETICS rose 31.1% to $62.4 million. In constant currency excluding COVID-19 related revenues, sales grew 32.4%. Adjusted operating loss declined from $72.0 million to $55.9 million. The company reported performing 317,062 analyses on SOPHiA DDM, a 20% growth in volume including COVID-related analysis or 27% excluding them. The number of core genomics customers increased from 434 to 450, including nine new US core genomics. Thirty-six new solid tumor customers were signed, resulting in 129 customers using solid tumor applications. Of these, over 50 homologous recombination deficiency (HRD) customers were added during with an over 150% revenue growth for HRD applications. The company’s total customers served were 770 hospitals with 450 recurring SOPHiaA DDM Platform customers. EMEA, North America, Latin American and APAC sales increased 26.0%, 59.3%, 32.9% and 25.4% to make up 70%, 17%, 6% and 6% of sales, respectively. The company reduced headcount during the second half of the year.
Singular Genomics’ full-year 2023 revenues increased 280.5% to $2.9 million (see Bottom Line) with a cumulative 24 systems shipped. Single Genomics develops sequencing and multi-omics technologies.
In March, SPT Labtech, a designer, developer and manufacturer of automated instrumentation and consumables for life science applications, announces a co-marketing collaboration with Roche to deliver a streamlined method for Illumina-compatible NGS library preparation. By leveraging SPT Labtech’s all-in-one automated liquid handling platform, firefly, this collaboration offers genomics researchers fully automated workflows for Roche’s KAPA EvoPlus and KAPA EvoPlus PCR-Free Kits The agreement covers RUO and diagnostic procedures.
Bayer and Thermo Fisher Scientific announced in March a collaboration to develop NGS-based companion diagnostic assays (CDx) together. The CDx will be developed using Thermo Fisher’s Oncomine Dx Express Test on the Ion Torrent Genexus Dx System, a fully integrated NGS platform that can deliver results on a patient’s tumor or liquid biopsy sample in as little as 24 hours.
In March, Fluent BioSciences (Fluent), a life sciences company providing what it calls simple, cost-effective, and highly scalable single-cell RNA sequencing solutions, announced the award of an NIH Small Business Innovation Research (SBIR) Phase II grant, funded by the National Institute of General Medical Sciences. This funding will support the commercialization of million-cell analysis kits enabled by low-cost, high-capacity sequencing by Ultima Genomics.
SOPHiA GENETICS’ fourth quarter 2023 revenues increased 27.4% to $17.0 million (see Bottom Line). In constant currency excluding COVID-19 related revenues, sales grew 26.9%. Adjusted operating loss expanded from $12.1 million to $13.3 million. The company signed 35 new core genomics customers during the quarter. SOPHiA GENETICS is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research.
2023 revenues for SOPHiA GENETICS rose 31.1% to $62.4 million. In constant currency excluding COVID-19 related revenues, sales grew 32.4%. Adjusted operating loss declined from $72.0 million to $55.9 million. The company reported performing 317,062 analyses on SOPHiA DDM, a 20% growth in volume including COVID-related analysis or 27% excluding them. The number of core genomics customers increased from 434 to 450, including nine new US core genomics. Thirty-six new solid tumor customers were signed, resulting in 129 customers using solid tumor applications. Of these, over 50 homologous recombination deficiency (HRD) customers were added during with an over 150% revenue growth for HRD applications. The company’s total customers served were 770 hospitals with 450 recurring SOPHiaA DDM Platform customers. EMEA, North America, Latin American and APAC sales increased 26.0%, 59.3%, 32.9% and 25.4% to make up 70%, 17%, 6% and 6% of sales, respectively. The company reduced headcount during the second half of the year.
SOPHiA GENETICS forecasts 2024 revenues to grow 25%–30% to $78–$81 million. Catalyst for growth is expected to include a new liquid biopsy offering, demand for increasingly complex solid tumors signatures, the US market, new offerings, and partnerships with biopharma. The company forecasts most of the growth from existing customers as labs absorb new sequencing system options, affecting customer readiness.
In March, Wobble Genomics announced it raised €9.9 million ($12.6 million). The round was led by Mercia Ventures and BGF and included IQ Capital, EOS Advisors, and Old College Capital, the University of Edinburgh’s venture fund. Wobble Genomics is developing long-read RNA sequencing technology. Eu-Startups reports the company has 10 employees and the company has raised £10.5 million ($13.4 million) to date.
STRmix, a provider of software for genomic forensics applications, announced in March the release of STRmix NGS. While not currently available for casework, STRmix NGS is designed for laboratories familiar with STRmix that are investigating future implementation of emergent NGS/MPS technology. This marks the first application of the STRmix technology for NGS, which employs a fully continuous approach for interpretation of NGS-generated short tandem repeat (STR) DNA profiles. This allows users to research the potential implementation and validation path of probabilistic genotyping (PG) alongside NGS chemistries and sequencing equipment.
Twist Bioscience (Twist), a company offering of high-quality synthetic DNA using its silicon platform, announced that its Twist Precision Dx NGS products are now EU in vitro diagnostic regulations (IVDR) compliant. The Precision Dx products are designed to enable panel sequencing within a clinical setting. Twist is collaborating with Platomics to enable laboratories to efficiently generate documentation on Platomics’ multi-stakeholder platform for workflows incorporating the Twist Precision Exome Dx Kit, and to help automate regulatory processes and accelerate compliance for laboratories and manufacturers.
In March, Twist announced the introduction of a new Human Pangenome Spike-in for the Twist Exome 2.0 panel, which was developed to enable researchers to detect a more complete view of genetic variation during whole exome sequencing. The Twist Human Pangenome Spike-in Panel targets 2.5 Mb of pangenome variants and can be spiked into the Twist Exome 2.0 to target more than 94% of the novel pangenome variants affecting coding sequences in the exome.
In March, Oxford Nanopore announced the early access launch of its all-in-one desk top sequencing device, the PromethION 2 Integrated (P2i), to complete its PromethION product range. Engineered with onboard computing capabilities, the P2i facilitates real-time base calling and post-run analysis directly within the device, eliminating the dependency on external computing resources. The self-contained device delivers up to 290 Gb of data per flow cell from native DNA, RNA or cDNA libraries and utilizes onboard NVIDIA Ampere architecture. The P2i builds upon the success of the P2 Solo, which launched in October 2022 and leased or sold over 700 units.
Invitae, a medical genetics company, announced in March the introduction of an update to Invitae Generation with Clinical Variant Modeling, a novel machine learning approach designed to aid clinical interpretation of genetic testing results to improve variant classification and reduce variants of uncertain significance (VUS). Clinical Variant Modeling was developed by leveraging Invitae's database of information on more than four million patients, including over two million analyzed DNA variants, and more than 100 million words of clinical descriptions.
In March, sequencer technology firm PacBio announced the PureTarget repeat expansion panel, a new solution designed to enable the comprehensive analysis of 20 genes associated with serious neurological disorders, including challenging-to-sequence genes with tandem repeat expansions. The new PureTarget panel started shipping on March 25.
In March, Wobble Genomics announced it raised €9.9 million ($12.6 million). The round was led by Mercia Ventures and BGF and included IQ Capital, EOS Advisors, and Old College Capital, the University of Edinburgh’s venture fund. Wobble Genomics is developing long-read RNA sequencing technology. Eu-Startups reports the company has 10 employees and the company has raised £10.5 million ($13.4 million) to date.
Product Introductions
In February, bioinformatics solutions firm Golden Helix announced the release of VSPGx, a pharmacogenomics solution for hospitals and testing labs. The PGx Variant Detection and Recommendation algorithm identifies pharmacogenomic diplotypes and annotates them with drug recommendations.STRmix, a provider of software for genomic forensics applications, announced in March the release of STRmix NGS. While not currently available for casework, STRmix NGS is designed for laboratories familiar with STRmix that are investigating future implementation of emergent NGS/MPS technology. This marks the first application of the STRmix technology for NGS, which employs a fully continuous approach for interpretation of NGS-generated short tandem repeat (STR) DNA profiles. This allows users to research the potential implementation and validation path of probabilistic genotyping (PG) alongside NGS chemistries and sequencing equipment.
Twist Bioscience (Twist), a company offering of high-quality synthetic DNA using its silicon platform, announced that its Twist Precision Dx NGS products are now EU in vitro diagnostic regulations (IVDR) compliant. The Precision Dx products are designed to enable panel sequencing within a clinical setting. Twist is collaborating with Platomics to enable laboratories to efficiently generate documentation on Platomics’ multi-stakeholder platform for workflows incorporating the Twist Precision Exome Dx Kit, and to help automate regulatory processes and accelerate compliance for laboratories and manufacturers.
In March, Twist announced the introduction of a new Human Pangenome Spike-in for the Twist Exome 2.0 panel, which was developed to enable researchers to detect a more complete view of genetic variation during whole exome sequencing. The Twist Human Pangenome Spike-in Panel targets 2.5 Mb of pangenome variants and can be spiked into the Twist Exome 2.0 to target more than 94% of the novel pangenome variants affecting coding sequences in the exome.
In March, Oxford Nanopore announced the early access launch of its all-in-one desk top sequencing device, the PromethION 2 Integrated (P2i), to complete its PromethION product range. Engineered with onboard computing capabilities, the P2i facilitates real-time base calling and post-run analysis directly within the device, eliminating the dependency on external computing resources. The self-contained device delivers up to 290 Gb of data per flow cell from native DNA, RNA or cDNA libraries and utilizes onboard NVIDIA Ampere architecture. The P2i builds upon the success of the P2 Solo, which launched in October 2022 and leased or sold over 700 units.
Invitae, a medical genetics company, announced in March the introduction of an update to Invitae Generation with Clinical Variant Modeling, a novel machine learning approach designed to aid clinical interpretation of genetic testing results to improve variant classification and reduce variants of uncertain significance (VUS). Clinical Variant Modeling was developed by leveraging Invitae's database of information on more than four million patients, including over two million analyzed DNA variants, and more than 100 million words of clinical descriptions.
In March, sequencer technology firm PacBio announced the PureTarget repeat expansion panel, a new solution designed to enable the comprehensive analysis of 20 genes associated with serious neurological disorders, including challenging-to-sequence genes with tandem repeat expansions. The new PureTarget panel started shipping on March 25.
In March, Revvity announced the introduction of a flexible end-to-end workflow solutions for newborn research, enabling users to utilize different instruments, reagents and databases based on a lab’s needs. The RUO offering from Revvity culminates in analysis and report, covering essential steps in the sequencing process. The solution enables identification of variants in more than 350 genes, complemented by a large database of carefully pre-curated variants. The offering includes dried blood spot collection and processing devices, Chemagic, kits and instruments for nucleic acid extraction, liquid handlers, and reagents library preparation, the VICTOR2 D Instrument for sample QC and software capabilities. The workflow is compatible with the Element Biosciences’ AVITI system and other NGS platforms. For labs interested in outsourcing the workflow, Revvity’s Clinical Genomic Services provides solutions from delivery of a sample collection kit to final report, or the flexibility to access sequence data or report only to augment the customer’s in-house capabilities.
seqWell, a provider of genomic library workflow solutions, announced in March the launch of its new ExpressPlex HT Library Preparation Kit, calling it the first commercially available NGS library preparation kit containing all the required reagents and indices to enable multiplexing up to 6,144 samples in a pre-plated in 384-well format. ExpressPlex HT uses a 90-minute workflow in a single mastermix reaction to streamline NGS library preparation through massive multiplexing, thereby enabling lower-cost, high-throughput sequencing of plasmids, amplicons and other synthetic constructs used in synthetic biology, according to the firm.
In March, Fluent BioSciences announced early access availability of new kits and reagents for direct CRISPR guide capture in particle-templated instant partitions (PIPseq-CRISPR). The PIPseq platform provides an instrument and microfluidics-free approach for single-cell analysis. The early access kits allow for universal capture of CRISPR guide-RNA in addition to 3' mRNA capture from single-cell suspensions. Although current PIPseq kits provide compatibility with polyadenylated reporter guides for CROP-seq compatible assays, the newly released PIPseq chemistry generalizes the approach across any CRISPR-Cas9 compatible application, according to the company. Initial PIPseq-CRISPR kits will provide up to 10,000 captured cells per reaction, but applications scaling to 100,000 and 1,000,000 cell capture scales per single-tube reaction are planned for release later this year.
Watchmaker Genomics, a supplier of products for molecular analysis, announced in March the release of the Watchmaker mRNA Library Prep Kit. The Kit generates high-quality mRNA libraries in under five hours with fewer handling and purification steps, according to the firm. Features include support for input amounts ranging from 2.5 ng to 1,000 ng of total RNA.
seqWell, a provider of genomic library workflow solutions, announced in March the launch of its new ExpressPlex HT Library Preparation Kit, calling it the first commercially available NGS library preparation kit containing all the required reagents and indices to enable multiplexing up to 6,144 samples in a pre-plated in 384-well format. ExpressPlex HT uses a 90-minute workflow in a single mastermix reaction to streamline NGS library preparation through massive multiplexing, thereby enabling lower-cost, high-throughput sequencing of plasmids, amplicons and other synthetic constructs used in synthetic biology, according to the firm.
In March, Fluent BioSciences announced early access availability of new kits and reagents for direct CRISPR guide capture in particle-templated instant partitions (PIPseq-CRISPR). The PIPseq platform provides an instrument and microfluidics-free approach for single-cell analysis. The early access kits allow for universal capture of CRISPR guide-RNA in addition to 3' mRNA capture from single-cell suspensions. Although current PIPseq kits provide compatibility with polyadenylated reporter guides for CROP-seq compatible assays, the newly released PIPseq chemistry generalizes the approach across any CRISPR-Cas9 compatible application, according to the company. Initial PIPseq-CRISPR kits will provide up to 10,000 captured cells per reaction, but applications scaling to 100,000 and 1,000,000 cell capture scales per single-tube reaction are planned for release later this year.
Watchmaker Genomics, a supplier of products for molecular analysis, announced in March the release of the Watchmaker mRNA Library Prep Kit. The Kit generates high-quality mRNA libraries in under five hours with fewer handling and purification steps, according to the firm. Features include support for input amounts ranging from 2.5 ng to 1,000 ng of total RNA.
Sales & Orders of Note
In February, PacBio announced in its quarterly conference call that the Radbound University in the Netherlands added a second Revio sequencer, which will be used for rare disease research. Children’s Mercy Hospital of Kansas City ordered its third Revio to continues its effort to consolidate tests for genetics and epigenetics. In March, PacBio announced that the University of Tartu, host of Estonia's National Biobank, chose the Revio HiFi sequencing system to sequence 10,000 whole human genomes. The announcement follows funding from the European Commission and the Estonian government to help Estonia adopt personalized medicine at scale and adapt public health systems to the biology of its population. The University will also support the EU's 1+ Million Genomes initiative.
TrendBio, a supplier of medical research instruments and consumables in Australia and New Zealand, announced in March the installation of the Element Biosciences AVITI system at Australia’s Garvan Institute of Medical Research.
In March, SOPHiA GENETICS announced that the Universidad de Costa Rica El Centro de Investigación en Cirugía y Cáncer (CICICA) is now live on the SOPHiA DDM Platform. The Surgery and Cancer Research Center is using SOPHiA GENETICS to expand its ability to trace, diagnose and treat rare and inherited diseases among Costa Ricans.
Also in March, SOPHiA GENETICS announced that Canada’s University of Saskatchewan (USask) as its first HRD customer in Canada. USask will implement the SOPHiA DDM Platform for use in its clinical trial, which aims to substantially improve the quality of life for ovarian cancer patients through expanded genetic testing.
TrendBio, a supplier of medical research instruments and consumables in Australia and New Zealand, announced in March the installation of the Element Biosciences AVITI system at Australia’s Garvan Institute of Medical Research.
In March, SOPHiA GENETICS announced that the Universidad de Costa Rica El Centro de Investigación en Cirugía y Cáncer (CICICA) is now live on the SOPHiA DDM Platform. The Surgery and Cancer Research Center is using SOPHiA GENETICS to expand its ability to trace, diagnose and treat rare and inherited diseases among Costa Ricans.
Also in March, SOPHiA GENETICS announced that Canada’s University of Saskatchewan (USask) as its first HRD customer in Canada. USask will implement the SOPHiA DDM Platform for use in its clinical trial, which aims to substantially improve the quality of life for ovarian cancer patients through expanded genetic testing.
Life Science Consumables
Company Announcements
Takara Bio’s Reagents sales for the fiscal nine months (ending December 31, 2023) declined 56.2% to ¥22,989 million ($155.6 million) to make up 77% of total company sales (see Bottom Line). Sales declined due to the impact of lower sales of COVID-related revenue, which fell 97.0% to make up 4% of segment sales. General Research reagent sales grew 2.2% to make up the remainder of segment revenue. Instrument sales dropped 40.9% to ¥638 million ($4.3 million) in part due to declining COVID-related demand. The company forecasts fiscal full-year Reagent sales to decline 50.3% to ¥32,792 million ($221.9 million). Takara Bio sells around 10,000 research reagents for genetic and cellular research and provides PCR instruments and cellular analysis devices.Bioz announced in January its partnership with Innovative Research. Innovative Research is a supplier of lab reagents, including plasma, serum, tissues, and proteins with a portfolio of over 65,000 human and animal biologicals. This new partnership supports Innovative Research's customers by bringing real-time product application data directly to its product webpages in the form of interactive digital web widgets called Bioz Badges.
In February, MIP Discovery announced it closed a £7 million (~$9 million) Series A financing round, led by Mercia Ventures. Existing investor Calculus Capital also participated in the round, along with Angel investors. The investment marks a pivotal change for MIP Discovery as the company refocuses its mission on improving the downstream processing of cell and gene therapies. MIP Discovery’s non-biological affinity reagents support a new approach to viral vector characterization, viral vector purification, and safety and QC processes, such as the detection and removal of impurities.
In March, ACROBiosystems, a provider of tools and solutions used from discovery to the clinic, announced a new corporate initiative to support ex vivo cell manufacturing and manufacturers of cell and gene therapies. This commitment was reflected in the recent launch of GMP-grade DLL4, a safer recombinant protein alternative to DLL4 feeder cells often used in iPSC-derived T cell manufacturing. With the launch of this initiative, ACROBiosystems seeks to stratify its products under a cell therapy modality-oriented perspective, streamlining the transition from research to the clinic by offering progressive reagents at each stage.
GenScript Biotech’s 2023 Life-Science Services and Products Sales (LSG) increased 14.5% to $412.9 million to make up 49% of total company sales. Adjusted operating loss for LSG increased 19.3% to $78.3 million. The division reported strength in demand for molecular biology, protein, and peptide products. LSG offers comprehensive life sciences research services and products including custom gene synthesis and molecular biology, custom protein expression and purification, custom peptide synthesis, antibody production, and custom cell line development, catalog antibodies, catalog kits, and eStain and eBlot.
External revenues in 2023 for GenScript Biotech LSG, which exclude intersegment sales, totaled $404.5 million for a 15.6% increase, up 16.4% in constant currency, with total customer numbers of 57,000, up from 53,000. For external LSG sales, US and European revenues grew more than 20% and 25%, respectively, while Asia Pacific sales declined 7%. The company forecasts 2004 LSG sales to external customers to grow around 15%–20%.
Abcam, a Danaher company, announced in March the appointment of Markus Lusser as President. He joined Danaher in 2011 and most recently served as Vice President and Chief Customer Officer for the Life Sciences Innovations Group. Abcam has more than 1,750 associates and serves 750,000 researchers worldwide.
In March, Proteintech announced that its branch in Martinsried near Munich, Germany, moved into its new laboratory and office space. The new building houses R&D, production, logistics and administration in an area more than three times larger than its previous space. In 2020, the Proteintech acquired ChromoTek (see IBO 11/2/20), the gradual integration of which enabled new sales markets and channels for the products manufactured in Martinsried. The Martinsried site also serves as a central logistics hub for all Proteintech products for customers in the EU. Proteintech is a manufacturer of antibodies, proteins, nanobodies and immunoassays.
Alpha Teknova’s fourth quarter 2023 sales fell 0.3% to $7.9 million (see IBO 3/19/24). Sales of Lab Essentials were down 3.5% to make up 85% of revenues, while Clinical Solutions and Other sales grew 13.9% and 62.2% to make up 11% and 4%, respectively. Adjusted EBITDA was a loss of $5.4 million compared to a loss of $8.1 million a year ago. The company offers three primary product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
In 2023, Alpha Teknova’s revenues dropped 11.4% to $36.7 million. Lab Essentials, Clinical Solutions and Other revenue declined 9.4%, 20.2% and 4.7% to account for 70%, 18% and 3% of revenues, respectively. Adjusted EBITDA showed a loss of $19.2 million compared to a loss of $21.9 million. The company reported 34 Clinical Solutions customers. The number of Lab Essentials customers declined 13% to 2,822, primarily due to SKU rationalization. US sales dropped 12.7% to $35 million, while international sales rose 27.9% to $1.7 million. One customer, a distributor, accounted for 18% of total revenues.
Alpha Teknova forecasts 2024 revenues to grow to $35–$38 million, essentially flat, including roughly 10% growth in Lab Essentials and the remainder of growth coming from the Clinical Solutions business. The company estimates adjusted EBITDA breakeven revenue to be $50–$55 million, which it commented may be achievable in 2025. The company reported cash and cash equivalents of $28 million as of December 31, 2023. Subsequently, this year, the company announced an amendment to its credit facility.
SPT Labtech and RevoluGen, a UK genomics company, announced in February the successful automation of RevoluGen’s Fire Monkey high molecular weight (HMW) DNA extraction chemistry in a bead-based format using SPT Labtech’s firefly automate liquid handling platform. The automated protocol enables the processing of up to 96 samples in parallel to prepare high molecule weight DNA suitable for library preparation for long-read sequencing in under two hours.
TriLink BioTechnologies (TriLink), a Maravai LifeSciences company and provider of life science reagents and services, announced in March it was granted patents by the China National Intellectual Property Administration (CNIPA) and the Canadian Intellectual Property Office (CIPO). Patent numbers ZL 2023 1 0734863.0 and CA 2999274 are related to TriLink’s CleanCap technology for the co-transcriptional capping of mRNAs. These new issuances add new jurisdictions to the list of other major world markets in which CleanCap technology is already patented, including the US, EU, Australia, Japan, Korea, and Hong Kong.
Maravai LifeSciences’ fourth quarter 2023 sales declined 63.8% to $74.1 million (see IBO 3/5/24). Adjusted EBITDA was $20.5 million versus $129.8 million in the prior like period. Nucleic Acid Production (NAP) sales dropped 68.9%, and Biologics Safety Testing (BST) sales decreased 0.7% to make up 79% and 21% of revenues, respectively. NAP revenue included $18.4 millions of COVID-19-related CleanCap revenue, which was $105.2 million lower than the same period in 2022. The NAP business sells mRNA, RNA Capping (CleanCap), oligonucleotides, oligonucleotide inputs, nucleoside triphosphates, custom nucleic acid chemistry, plasmid DNA and specialty enzymes. The BST business offers HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, viral clearance prediction kits, ancillary reagents, and custom services.
Alpha Teknova’s fourth quarter 2023 sales fell 0.3% to $7.9 million (see IBO 3/19/24). Sales of Lab Essentials were down 3.5% to make up 85% of revenues, while Clinical Solutions and Other sales grew 13.9% and 62.2% to make up 11% and 4%, respectively. Adjusted EBITDA was a loss of $5.4 million compared to a loss of $8.1 million a year ago. The company offers three primary product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
In 2023, Alpha Teknova’s revenues dropped 11.4% to $36.7 million. Lab Essentials, Clinical Solutions and Other revenue declined 9.4%, 20.2% and 4.7% to account for 70%, 18% and 3% of revenues, respectively. Adjusted EBITDA showed a loss of $19.2 million compared to a loss of $21.9 million. The company reported 34 Clinical Solutions customers. The number of Lab Essentials customers declined 13% to 2,822, primarily due to SKU rationalization. US sales dropped 12.7% to $35 million, while international sales rose 27.9% to $1.7 million. One customer, a distributor, accounted for 18% of total revenues.
Alpha Teknova forecasts 2024 revenues to grow to $35–$38 million, essentially flat, including roughly 10% growth in Lab Essentials and the remainder of growth coming from the Clinical Solutions business. The company estimates adjusted EBITDA breakeven revenue to be $50–$55 million, which it commented may be achievable in 2025. The company reported cash and cash equivalents of $28 million as of December 31, 2023. Subsequently, this year, the company announced an amendment to its credit facility.
Gene-Based Analysis
Company Announcements
In February, QIAGEN announced that two newly launched environmentally friendlier QIAwave nucleic-acid extraction kits, the QIAwave RNA Plus Mini Kit and QIAwave DNA/RNA Mini Kit, received the ACT Environmental Impact Factor Label, bringing the number of QIAGEN products with this recognition to eight. In awarding the ACT (Accountability, Consistency, and Transparency) labels, My Green Lab found that the two new QIAwave products had an up to 27% improvement in the Environmental Impact Factor when compared to the respective QIAGEN standard kits. Also, QIAGEN’s R&D lab for sample technologies at its European operational headquarters in Hilden, Germany, has achieved the Platinum certification level in a review by My Green Lab. QIAGEN has set a roadmap to have all its Life Sciences labs at the Hilden site certified by My Green Lab.SPT Labtech and RevoluGen, a UK genomics company, announced in February the successful automation of RevoluGen’s Fire Monkey high molecular weight (HMW) DNA extraction chemistry in a bead-based format using SPT Labtech’s firefly automate liquid handling platform. The automated protocol enables the processing of up to 96 samples in parallel to prepare high molecule weight DNA suitable for library preparation for long-read sequencing in under two hours.
TriLink BioTechnologies (TriLink), a Maravai LifeSciences company and provider of life science reagents and services, announced in March it was granted patents by the China National Intellectual Property Administration (CNIPA) and the Canadian Intellectual Property Office (CIPO). Patent numbers ZL 2023 1 0734863.0 and CA 2999274 are related to TriLink’s CleanCap technology for the co-transcriptional capping of mRNAs. These new issuances add new jurisdictions to the list of other major world markets in which CleanCap technology is already patented, including the US, EU, Australia, Japan, Korea, and Hong Kong.
Maravai LifeSciences’ fourth quarter 2023 sales declined 63.8% to $74.1 million (see IBO 3/5/24). Adjusted EBITDA was $20.5 million versus $129.8 million in the prior like period. Nucleic Acid Production (NAP) sales dropped 68.9%, and Biologics Safety Testing (BST) sales decreased 0.7% to make up 79% and 21% of revenues, respectively. NAP revenue included $18.4 millions of COVID-19-related CleanCap revenue, which was $105.2 million lower than the same period in 2022. The NAP business sells mRNA, RNA Capping (CleanCap), oligonucleotides, oligonucleotide inputs, nucleoside triphosphates, custom nucleic acid chemistry, plasmid DNA and specialty enzymes. The BST business offers HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, viral clearance prediction kits, ancillary reagents, and custom services.
Maravai LifeSciences’ 2023 sales dropped 67.3% to $224.8 million. NAP sales declined 72.4% and BST sales fell 8.2% to represent 92% and 8% of sales, respectively. NAP sales included an estimated $60.8 million of COVID-19 related CleanCap revenue, which was $539.0 million lower than the prior year. The company’s top 10 customers accounted for less than 50% of total revenues. Over 170 discovery customers are working with the recently launched CleanCap M6 product. Geographically, NAP sales in North America, Europe/the Middle East/Asia and Asia Pacific were down 63.3%, 91.7%, 11.5% to account for 51%, 15% and 34% of segment revenue, while Latin and Central America sales grew 41.7% to account for less than 1%. For BST, for the respective regions, sales declined 2.8%, 11.9%, 10.5% and 51.4% to make up 41%, 24%, 34% and 1% of segment sales. Adjusted EBITDA for the company dropped 89.8% to $65.3 million. By segment, NAP adjusted EBITDA declined 87.1% to $82.7 million, while BST adjusted EBITDA fell 14.5% to $46.9 million.
Maravai LifeSciences forecasts 2024 sales to increase 18%–27% to $265–$285 million. NAP sales are estimated to be down around 8% at the midpoint, while BST sales should grow low to mid-single digits.
Elegen, a producer of cell-free synthetic DNA, announced in March the commercial launch of an enhancement to ENFINIA DNA that provides researchers with a reliable supply of very high complexity DNA in as fast as 10 business days, according to the firm.
In March, genomics solutions provider Integrated DNA Technologies (IDT) announced it expanded its gene synthesis offerings with a new custom vector on-boarding tool. The solution is designed for researchers who want to skip in-house cloning steps and move quickly into functional studies with 100% sequence-verified clonal DNA. Researchers can submit their vector sequence via IDT's website without having to contact a sales representative. After a one-time cost of $500 for onboarding a custom vector, customers will not incur additional fees when ordering inserts in their custom vector, and no minimum order is required. As a large-scale provider of synthetic DNA, IDT can make gene fragments between 125 bp to 3 kb and custom genes between 25 bp to 5 kb. Genes greater than 5 kb require custom quoting. Looking ahead to the second half of 2024, IDT plans to leverage its expanded US-based synthetic biology manufacturing facility footprint.
In February, Charles River Laboratories International (Charles River) announced that it entered into an agreement with Pluristyx, a provider of tools, technologies, and services for the development of cell therapies. The collaboration provides Charles River with broad access to stem cell lines, including embryonic stem (ES) cells and iPSCs as research tools to support development of new therapeutics. Through the agreement, Charles River will distribute Pluristyx’s wild-type and genetically engineered iPSCs as well as its portfolio of normal and disease state embryonic stem (ES) cell lines and will exclusively offer specific pluripotent stem cell lines derived under Good Tissue Practice to support a path to the clinic.
Maravai LifeSciences forecasts 2024 sales to increase 18%–27% to $265–$285 million. NAP sales are estimated to be down around 8% at the midpoint, while BST sales should grow low to mid-single digits.
Product Introductions
In March, Zymo Research, a company supplying molecular tools tailored for the biotech sector, announced the release of PureRec RNase A, an animal-free recombinant RNase. It is made in the US with bulk orders available.Elegen, a producer of cell-free synthetic DNA, announced in March the commercial launch of an enhancement to ENFINIA DNA that provides researchers with a reliable supply of very high complexity DNA in as fast as 10 business days, according to the firm.
In March, genomics solutions provider Integrated DNA Technologies (IDT) announced it expanded its gene synthesis offerings with a new custom vector on-boarding tool. The solution is designed for researchers who want to skip in-house cloning steps and move quickly into functional studies with 100% sequence-verified clonal DNA. Researchers can submit their vector sequence via IDT's website without having to contact a sales representative. After a one-time cost of $500 for onboarding a custom vector, customers will not incur additional fees when ordering inserts in their custom vector, and no minimum order is required. As a large-scale provider of synthetic DNA, IDT can make gene fragments between 125 bp to 3 kb and custom genes between 25 bp to 5 kb. Genes greater than 5 kb require custom quoting. Looking ahead to the second half of 2024, IDT plans to leverage its expanded US-based synthetic biology manufacturing facility footprint.
Cell-Based Analysis
Company Announcements
In January, Cellcolabs, a spin-out of the Karolinska Institute in Sweden specializing in manufacturing both research- and GMP-grade MSCs, and REPROCELL, which calls itself Japan’s first iPSC company, announced they partnered to globally distribute MSCs and MSC derivatives manufactured by Cellcolabs for research and clinical applications. This agreement also includes exclusive distribution in Japan.In February, Charles River Laboratories International (Charles River) announced that it entered into an agreement with Pluristyx, a provider of tools, technologies, and services for the development of cell therapies. The collaboration provides Charles River with broad access to stem cell lines, including embryonic stem (ES) cells and iPSCs as research tools to support development of new therapeutics. Through the agreement, Charles River will distribute Pluristyx’s wild-type and genetically engineered iPSCs as well as its portfolio of normal and disease state embryonic stem (ES) cell lines and will exclusively offer specific pluripotent stem cell lines derived under Good Tissue Practice to support a path to the clinic.
ATCC, a biological materials management and standards organization, and Tissue Dynamics, a pharma-tech company integrating advanced AI tools with bionic human organoids, announced in February a partnership to develop workflow friendly cardiac organoids–based kits for improved cardiac safety testing in drug development. The collaboration will be done under the Israel-US Binational Industrial Research and Development Foundation (BIRD) framework, which awarded both companies a two-year grant. Tissue Dynamics partnered with Israel’s Hebrew University of Jerusalem to develop the world’s first mature self-paced multi-chambered cardiac organoid model, using ATCC cells. Tissue Dynamics’ partnership with ATCC aims to advance this cardiac organoid model for industrial use.
In February, bit.bio and Ginkgo Bioworks (Gingko), which is building a platform for cell programming and biosecurity, announced bit.bio as an inaugural partner of the Ginkgo Technology Network. As a Network partner, bit.bio’s ioCells portfolio of human cells for research and drug discovery can be integrated into Ginkgo’s platform ecosystem. They are defined human cells that have inherent experimental scalability. bit.bio is a synthetic biology company focused on human cells that is advancing medicine and enabling curative treatments (UN SDG3).
In March, bit.bio announced the first project within a multi-year collaboration agreement with the Michael J. Fox Foundation for Parkinson's Research (MJFF) to prioritize the development and delivery of a range of human cell products relevant to Parkinson’s disease (PD). Both wild type human cells and physiologically relevant disease model cells will be generated through individual project agreements. Funding to bit.bio by MJFF will be allocated on a project-by-project basis. The first project will prioritize the discovery of transcription factor combinations for a relevant human cell type in PD and the development of that cell type into a product for the PD research community.
In March, Newcells Biotech, whose 3D models are used in drug development and reduce reliance on animal testing, announced it raised a further £2.35 million ($2.98 million). It secured funding from existing investors including the Northeast Venture Fund, supported by the European Regional Development Fund, and managed by Mercia Ventures, Mercia’s own funds and Northstar Ventures. This brings the total raised by the company to date to over £12 million ($15 million). The company, which employs a 49-strong team, increased revenue by 56% in the last financial year and plans to create 10 new jobs in the year ahead.
In February, bit.bio and Ginkgo Bioworks (Gingko), which is building a platform for cell programming and biosecurity, announced bit.bio as an inaugural partner of the Ginkgo Technology Network. As a Network partner, bit.bio’s ioCells portfolio of human cells for research and drug discovery can be integrated into Ginkgo’s platform ecosystem. They are defined human cells that have inherent experimental scalability. bit.bio is a synthetic biology company focused on human cells that is advancing medicine and enabling curative treatments (UN SDG3).
In March, bit.bio announced the first project within a multi-year collaboration agreement with the Michael J. Fox Foundation for Parkinson's Research (MJFF) to prioritize the development and delivery of a range of human cell products relevant to Parkinson’s disease (PD). Both wild type human cells and physiologically relevant disease model cells will be generated through individual project agreements. Funding to bit.bio by MJFF will be allocated on a project-by-project basis. The first project will prioritize the discovery of transcription factor combinations for a relevant human cell type in PD and the development of that cell type into a product for the PD research community.
In March, Newcells Biotech, whose 3D models are used in drug development and reduce reliance on animal testing, announced it raised a further £2.35 million ($2.98 million). It secured funding from existing investors including the Northeast Venture Fund, supported by the European Regional Development Fund, and managed by Mercia Ventures, Mercia’s own funds and Northstar Ventures. This brings the total raised by the company to date to over £12 million ($15 million). The company, which employs a 49-strong team, increased revenue by 56% in the last financial year and plans to create 10 new jobs in the year ahead.
Product Introductions
Takara Bio USA announced in February that it plans to introduce two automated single-cell total RNA-seq and DNA-seq library preparation kits. The Shasta Total RNA-Seq Kit will detect splicing isoforms, gene fusions and non-polyadenylated RNAs through full-length transcriptome profiling of up to 100,000 single cells per run. Similarly, the Shasta Whole-Genome Amplification Kit will enable novel insights into tumor heterogeneity through CNV and SNP analyses of over 1,500 single cells at once. Takara Bio’s new total RNA-seq solution will allow researchers to automatically prepare full-length libraries from up to 100,000 single cells and up to 96 samples per experiment with only two rounds of barcoding. Takara Bio’s non-targeted, whole-genome approach will allow for detection of CNVs—including arm-level CNVs—and SNVs in over 1,500 single cells and up to eight samples per run.In February, Biotium, a supplier of fluorescent dyes for life science research, announced the expansion of its NucSpot Nuclear Stains lineup for nuclear counterstaining. NucSpot Nuclear Stains are membrane-impermeant, targeting the nucleus selectively with minimal fluorescence until binding to DNA, according to the company, enabling no-wash nuclear staining. The company now offers nine colors spanning the fluorescence spectrum from green to near-IR.
INDIGO Biosciences (INDIGO) announced in February the release of new cell-based reporter assays for the family of human adrenergic receptors, including ADRA1A, ADRA1B, ADRA1D, ADRB1 and ADRB2. INDIGO’s adrenergic receptor assay kits contain all materials needed to perform the assay, including cryopreserved optimized reporter cells, media for use in recovering the cryopreserved cells and for diluting test samples, reference compound, luciferase detection reagent, a cell culture–ready assay plate and a detailed protocol. INDIGO is a supplier of receptor reporter assay kits.
In February, Parse Biosciences, a provider of single-cell sequencing solutions, announced a significant update to its flagship Evercode Whole Transcriptome (WT) products, which will be available to ship in mid-March. With the version 3 chemistry, customers now have the option of fixing up to 96 samples simultaneously in plate format. The new chemistry is available for the entire WT product line: WT Mini for experiments up to 10,000 cells or nuclei, WT for experiments up to 100,000 cells or nuclei, WT Mega for experiments up to 1,000,000 cells or nuclei, and Fixation for cells or nuclei.
BioSkryb Genomics, a company specializing in single-cell technology, announced the commercial launch in March of its new ResolveDNA Whole Genome and ResolveOME Whole Genome and Transcriptome Single-Cell Core Kits, which are now available to US and international customers. The new single-cell core kits leverage the power of primary template-directed amplification (PTA) in an end-to-end kitted workflow. The total workflow time has been reduced to under eight hours for both products. The ResolveDNA kit allows researchers to resolve clonal architectures that are defined by genome-wide co-occurrence of SNVs, CNVs and structural variants (SVs). The ResolveOME Whole Genome and Transcriptome Single-Cell Core Kit leverages its PTA-based whole genome analysis technology to couple each single cell’s whole genome with its full-length whole transcriptome. Unifying both DNA and RNA from every cell eliminates the need for splitting samples or inferring trends between single-analyte data sets, according to the company.
In March, Ajinomoto launched a new version of its StemFit iPSC expansion medium. The enhanced version of its StemFit products is designed to improve the growth and pluripotency of iPSC and meet the GMP standards for APIs. Ajinomoto supplies iPSC and ES cell culture media.
Slingshot Bio introduced in March what it called a first-of-its-kind suite of synthetic cells that express controlled amounts of cell therapy–relevant markers including BCMA and CD19. Another key addition to this product portfolio is a product containing lymphocyte subsets, which is comprised of defined populations of cells relevant to patient characterization standardization. These products enable cell therapy developers and researchers to improve their analytical methodologies by providing consistent, cost-effective controls for accurately profiling patients and evaluating therapies, according to the company. They are designed for use in flow cytometry assays.
Protein-Based Analysis
Company Announcements
ArcticZymes Technologies (ArcticZymes) reported 2023 sales declined 13.2% to NOK 118.9 million ($11.7 million) (see Bottom Line). Biomanufacturing sales fell 18.6% to make up 47% of company sales. Molecular Tools sales grew 18.6%, excluding COVID-related sales, to account for the remainder. In January, the company closed an Oslo site, affecting four positions. The change is part of a corporate restructuring as the company revises its strategy to focus on biomanufacturing, partnerships and commercial execution. ArcticZymes Technologies is focused on the development, manufacturing, and commercialization of novel recombinant enzymes for use in molecular research, IVD and biomanufacturing.In February, MyBio announced it will distribute products for Nordmark Biochemicals, a manufacturer of collagenase and protease, in Ireland and Northern Ireland.
Product Introductions
ArcticZymes announced in January the debut of Salt Active Nuclease High Quality GMP Grade (SAN HQ GMP) for the enzymatic removal of contaminating DNA from therapeutic products such as viral vectors and vaccines. With the new SAN HQ GMP, ArcticZymes extends its portfolio to include a GMP-grade nuclease.| Delivering Growth - in Asia and Beyond. |
| | |
| Website: dksh.com/lab-solutions | Email: marketing.tec@dksh.com |